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Abstract
Cellular therapies targeted at stimulating therapeutic angiogenesis in individuals with critical
limb ischemia (CLI) have been under intense investigation. Hematopoietic progenitor cells
(HPC) derived from umbilical cord blood have been previously shown to support limb
revascularization in animal models of CLI, despite limited cell survival at the site of
ischemia. This study attempted to improve HPC survival after transplantation and prolong
pro-angiogenic function using human decellularized adipose tissue (hDAT) as a novel cell
delivery platform. Compared to HPC conventionally grown on tissue-cultured plastic, hDAT
scaffolds were shown to promote viability and proliferation of seeded HPC, and had cellinstructive effects on HPC differentiation through increased expression of cell surface
markers enriched on the monocyte/macrophage lineage. For in vivo transplantation studies in
a surgically-induced model of CLI, hDAT-seeded scaffolds promoted an accelerated and
sustained recovery in limb perfusion, improved functional limb use and increased CD31+
capillary density compared to unseeded hDAT controls.

Keywords
Peripheral artery disease, hematopoietic stem and progenitor cells, cell-based therapies,
decellularized tissue, biomaterials, therapeutic angiogenesis, human decellularized adipose
tissue, umbilical cord blood, aldehyde dehydrogenase, transplantation.
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Summary for Lay Audience
Peripheral artery disease (PAD) caused by the accumulation of atherosclerotic plaque in the
distal extremities places an immense burden on national healthcare organizations. Individuals
with large end-stage occlusions typically present with symptoms such as gangrene, pain at
rest and non-healing ulcers and are commonly diagnosed with the most severe form of PAD
known as critical limb ischemia (CLI). Due to a lack of effective treatment options, many
patients require lower limb amputation to relieve symptoms and prevent mortality.
Fortunately, cellular therapies aimed at stimulating new blood vessel growth and reducing
amputation rates have been under intense investigation as an alternative treatment for CLI.
Umbilical cord blood (UCB) has been found to contain a rare population of hematopoietic
progenitor cells (HPC) that have demonstrated robust regenerative abilities when utilized in
animal models of CLI. However, due to the harsh environment that the cells were being
introduced into, cell survival and retention at the site of injection remained low. This project
aimed to improve HPC survival and retention using a novel cell delivery bioscaffold derived
from human adipose tissue commonly discarded as surgical waste. The adipose-derived
bioscaffolds were shown to increase HPC survival and proliferation in vitro, and were shown
to induce HPC differentiation towards mature cell populations involved in tissue repair.
When translated into a relevant animal model of CLI, HPC delivered within the adipose
tissue-derived bioscaffold facilitated increased limb blood flow and improved functional
metrics of limb use. Overall, these studies aimed to provide pre-clinical proof of concept for
improved cell therapies harnessing cell supportive biomaterials for CLI.

ii

Acknowledgements
I would first like to acknowledge and express my deepest gratitude towards my supervisors,
Dr. David Hess and Dr. Lauren Flynn, for their immense contributions to this Master’s thesis.
This project would not have been possible without their unwavering support, guidance and
encouragement, and it has been an absolute honour to be a part of their research team and
represent them at conferences. Thank you for giving me the autonomy to explore research at
my own pace while keeping me grounded and motivated when my experiments didn’t go to
plan. Their mentorship has been instrumental in my evolution as an individual and I will
always look back fondly at the memories and relationships I have built in each of their labs.
I would also like to thank my advisory committee members, Dr. Christopher Ellis and Dr.
Doug Hamilton, for their continuous mentorship and knowledgeable insight over the course
of this project. Your passion to research and continuous support has been inspiring.
To all the current and past members of the Hess and Flynn labs, thank you for warmly
accepting me and providing me with so many great memories in and out of the lab. All of
your support was invaluable to my development and I am fortunate to have made so many
friends throughout my Masters. A special thanks goes out to Stephen Sherman, Tyler Cooper,
Ruth Elgamal, Brianna Ananthan, Sarah Krause, Gillian Bell, Fiona Serack, Luka Kremic,
Anna Kornmuller and Tim Han for their assistance and direct contributions to this project.
To Kristin Chadwick at the London Regional Flow Cytometry Facility, thank you for all of
your assistance with the cell sorts and flow cytometry completed on this project. I cannot
overstate the value of your expertise and I will miss chatting with you during my weekly sort.
To my beautiful partner, Sabrina Jackson, words cannot express how thankful I am for the
love and support you have provided me over the past 5 years and the sacrifices you have
made to make my dreams a reality. You have always been my rock and I am very excited
about the future we are building together. Forever and always, I love you.
Finally, To my parents, Deborah and Grant, step father Brian, and all my siblings, this thesis
is the culmination of your support and encouragement throughout my life and would not have
been possible without you. I love you all.
iii

Table of Contents
Abstract .................................................................................................................................i
Summary for Lay Audience ............................................................................................... ii
Acknowledgements ........................................................................................................... iii
Table of Contents................................................................................................................iv
List of Tables ................................................................................................................... viii
List of Figures .....................................................................................................................ix
List of Appendices ..............................................................................................................xi
List of Abbreviations ........................................................................................................ xii
Chapter 1.............................................................................................................................. 1
1 Introduction..................................................................................................................... 1
1.1 Cardiovascular biology ............................................................................................ 1
1.1.1

The endothelium .......................................................................................... 1

1.2 Cardiovascular disease ............................................................................................ 3
1.2.1

Atherosclerosis ............................................................................................ 3

1.2.2

Peripheral artery disease .............................................................................. 4

1.2.3

Current treatments for PAD ......................................................................... 6

1.3 Mechanisms of vascular regeneration ..................................................................... 6
1.3.1

Angiogenesis ............................................................................................... 7

1.3.2

Vasculogenesis ............................................................................................ 9

1.3.3

Arteriogenesis ............................................................................................ 10

1.4 Hematopoietic stem and progenitor cells .............................................................. 12
1.4.1

Hematopoietic stem cell development and role in hematopoiesis ............. 12

1.4.2

Hematopoietic stem and progenitor cell isolation and characterization .... 13

1.4.3

Aldehyde dehydrogenase ........................................................................... 16
iv

1.4.4

Aldehyde dehydrogenase as an alternative marker for progenitor cell
populations................................................................................................. 17

1.4.5

Alternative revascularization strategies for patients with PAD................. 18

1.5 The Use of Biomaterials as a Cell Delivery Platform ........................................... 24
1.5.1

The extracellular matrix............................................................................. 24

1.5.2

Biomaterial requirements .......................................................................... 26

1.5.3

Decellularized tissue biomaterials ............................................................. 27

1.5.4

Adipose tissue derived biomaterials .......................................................... 28

1.6 Project overview .................................................................................................... 30
1.7 Hypotheses............................................................................................................. 30
1.8 Objectives .............................................................................................................. 31
2 Materials and methods .................................................................................................. 32
2.1 HPC purification and expansion ............................................................................ 32
2.1.1

Purification of ALDHhi cells from umbilical cord blood .......................... 32

2.1.2

Expansion of ALDHhi HPC ....................................................................... 35

2.2 hDAT scaffold production ..................................................................................... 35
2.2.1

Adipose tissue decellularization protocol .................................................. 35

2.3 Preparation of hDAT suspension and scaffold fabrication .................................... 37
2.4 HPC seeding and extraction from hDAT scaffolds ............................................... 40
2.4.1

HPC seeding into hDAT scaffolds ............................................................ 40

2.4.2

Cell extraction from hDAT scaffolds ........................................................ 40

2.5 Cell viability, proliferation, ALDH-activity and phenotype analyses in vitro ...... 42
2.5.1

Cell viability .............................................................................................. 42

2.5.2

Cell proliferation........................................................................................ 42

2.5.3

ALDH Activity and Primitive Cell Surface Marker Expression ............... 43

2.5.4

Monocyte and macrophage marker expression ......................................... 43
v

2.6 Femoral Artery Ligation and Transplantation of HPC seeded hDAT Scaffolds ... 45
2.6.1

Animals ...................................................................................................... 45

2.6.2

Femoral Artery Ligation Surgery .............................................................. 45

2.6.3

Laser Doppler Perfusion Imaging and CatWalk Gait Analysis ................. 48

2.6.4

Histological evaluation of revascularization ............................................. 48

2.7 Statistics ................................................................................................................. 50
3 Results........................................................................................................................... 51
3.1 HPC within hDAT scaffolds demonstrated increased viability in vitro ................ 51
3.2 HPC within hDAT scaffolds demonstrated increased proliferation in vitro ......... 53
3.3 Culture in hDAT scaffolds did not affect primitive cell surface marker frequency
............................................................................................................................... 55
3.4 Culture in hDAT scaffolds stimulated an increase in cells with high aldehyde
dehydrogenase activity .......................................................................................... 57
3.5 Culture in hDAT scaffolds augments expression of monocyte/macrophage lineage
markers in HPC ..................................................................................................... 59
3.6 HPC culture on hDAT scaffolds show enhanced CD163 expression at 7 days .... 62
3.7 Mice treated with HPC delivered in hDAT scaffolds showed accelerated recovery
of limb perfusion ................................................................................................... 65
3.8 Mice treated with HPC delivered in hDAT scaffolds showed accelerated recovery
of limb use ............................................................................................................. 68
3.9 Mice treated with HPC delivered in hDAT scaffolds showed increased
intramuscular capillary density in the ischemic thigh ........................................... 70
4 Discussion ..................................................................................................................... 72
Chapter 5............................................................................................................................ 82
5 Conclusions and future directions................................................................................. 82
5.1 Summary of findings ............................................................................................. 82
5.2 Limitations and future recommendations .............................................................. 84
5.3 Conclusion ............................................................................................................. 88
References ......................................................................................................................... 89
vi

Appendices ...................................................................................................................... 113
Curriculum Vitae ............................................................................................................. 117

vii

List of Tables
Table 2.1 Antibody specifications for flow cytometry protocols ............................................ 44
Table 2.2 Specifications for immunohistochemistry protocols ............................................... 50

viii

List of Figures
Figure 1.1 Mechanisms of vascular regeneration .................................................................... 11
Figure 1.2 Overview of human hematopoietic hierarchy ........................................................ 15
Figure 2.1 Objective 1 methodology and timeline for the in vitro characterization of UCBderived HPC seeded into hDAT scaffolds ............................................................................... 34
Figure 2.2 Macroscopic overview for adipose tissue decellularization and scaffold fabrication
................................................................................................................................................. 39
Figure 2.3 Objective 2 methodology and timeline for the in vivo application of HPC
delivered in hDAT scaffolds in a immunodeficient mouse model of CLI .............................. 47
Figure 3.1 Culture in hDAT scaffolds increased HPC viability in vitro ................................. 52
Figure 3.2 Culture in hDAT scaffolds maintained HPC proliferation in vitro ........................ 54
Figure 3.3 Cells cultured in hDAT scaffolds and on TCP showed similar frequencies of
primitive phenotype ................................................................................................................. 56
Figure 3.4 HPC collected from the supernatant showed increased ALDH activity in vitro,
with reduced frequency of the primitive cell surface marker CD34 in the ALDHhi population
................................................................................................................................................. 58
Figure 3.5 Culture in hDAT scaffolds results in enhanced expression of
monocyte/macrophage lineage markers .................................................................................. 61
Figure 3.6 Culture in hDAT promotes CD163+ cell frequency for seeded HPC.................... 64
Figure 3.7 Mice treated with HPC seeded in hDAT scaffolds showed increased limb
perfusion following femoral artery and vein ligation and excision ......................................... 67
Figure 3.8 Mice treated with HPC delivered in hDAT scaffolds showed accelerated recovery
of limb use ............................................................................................................................... 69

ix

Figure 3.9 Mice treated with HPC delivered in hDAT scaffolds showed enhanced
intramuscular CD31 expression in the ischemic thigh ............................................................ 71

x

List of Appendices
Appendix 1. Supplementary Figures ............................................................................... 113
Appendix 2. Human Cell/Tissue Ethics Approval .......................................................... 114
Appendix 3. Animal Use Protocol Approval................................................................... 115

xi

List of Abbreviations
°C

Degrees Celsius

µL

Microliter

µm

Micrometer

3D

3 dimensional

ABAM

Antibiotic-antimycotic solution

ABI

Ankle brachial index

AGM

Aorta-gonad-mesonephros

ALDH

Aldehyde dehydrogenase

Ang1

Angiopoietin-1

Ang2

Angiopoietin-2

ANOVA

Analysis of variance

ASC

Adipose derived stem/stromal cells

AUC

Area under the curve

BAAA

BODIPY-aminoacetaldehyde

bFGF

Basic fibroblast growth factor

BFU-E

Erythrocyte blast forming unit

BM

Basement membrane

BM-MNC

Bone marrow mononuclear cells

BSA

Bovine serum albumin

CCAC

Canadian Council on Animal Care

CD

Cluster of differentiation

CFU-G

Granulocyte colony forming unit

CFU-GM

Granulocyte and macrophage colony forming unit

CFU-M

Macrophage colony forming unit

CFU-Mixed

Mixed colony forming unit
xii

CLI

Critical limb ischemia

cm

Centimeter

CVD

Cardiovascular disease

DAAA

Dansyl aminoacetaldehyde

DAB

3,3'-diaminobenzidine

DAPI

4',6-Diamidino-2-Phenylindole, Dihydrochloride

ddH2O

Double distilled water

DEAB

Diethylaminobenzaldehyde

DNA

Deoxyribonucleic acid

ECM

Extracellular matrix

EDTA

Ethylenediaminetetraacetic acid

EdU

5-ethynyl-2-deoxyuridine

EGF

Epidermal growth factor

EPC

Endothelial progenitor cells

FACS

Fluorescence activated cell sorting

FAL

Femoral artery ligation

FBS

Fetal bovine serum

FGF-16

Fibroblast growth factor-16

FGF-2

Fibroblast growth factor-2

Flt3L

Fms-related tyrosine kinase 3 ligand

FMO

Fluorescence minus one

g

Grams

GAG

Glycosaminoglycan

GM-CSF

Granulocyte-monocyte colony stimulating factor

GMP

Good manufacturing practices

GUSB

Beta-glucoronidase
xiii

hDAT

Human decellularized adipose tissue

HGF

Hepatocyte growth factor

HIF-1

Hypoxia-inducible factor-1

HIF-1a

Hypoxia-inducible factor 1 alpha

HIF-1b

Hypoxia-inducible factor 1 beta

HPC

Hematopoietic progenitor cell

HSC

Hematopoietic stem cell

HSPC

Hematopoietic stem and progenitor cells

ICAM-1

Intracellular adhesion molecule-1

IFN-a,b,g

Interferon-alpha, -beta or -gamma

IGF-1

Insulin-like growth factor-1

IL-8

Interleukin-8

IM

Intramuscular

IP

Intraperitoneal

IV

Intravascular

IV

Intravenous

kg

Kilogram

L

Liter

LDL

Low-density lipoprotein

LDPI

Laser Doppler perfusion imaging

Lin-

Lineage depleted

LRFCF

London Regional Flow Cytometry Facility

LT-HSC

Long-term hematopoietic stem cell

M

Molar

MCP-1

Monocyte chemoattractant protein-1

mg

Milligrams
xiv

mL

Milliliter

mM

Millimolar

mm

Millimeter

MMP

Matrix metallproteinases

MMP-2

Matrix metalloproteinase-2

MMP-9

Matrix metalloproteinase-9

MNC

Mononuclear cells

MPC

Multipotent progenitor cell

MSC

Mesenchymal stromal cells

MSPVII

Mucopolysaccharidosis type VII

NK

Natural killer

NOD/SCID

Non-obese diabetic/severe combined immune deficiency

OCT

Optimal cutting temperature

PAD

Peripheral artery disease

PBS

Phosphate buffered saline

PDGF

Platelet derived growth factor

PECAM-1

Platelet endothelial cell adhesion molecule-1

PlGF

Placental growth factor

PMSF

Phenylmethanesulphonylfluoride

PR

Perfusion ratio

RAR

Retinoic acid receptor

RBC

Red blood cell

RCT

Randomized clinical trial

ROS

Reactive oxygen species

rpm

Rotations per minute

RXR

Retinoid X receptor
xv

SCF

Stem cell factor

SDF-1

Stromal derived growth factor-1

SEM

Standard error of the mean

SMC

Smooth muscle cells

SPB

Sorensen’s phosphate buffer

SSC

Side scatter

ST-HSC

Short-term hematopoietic stem cell

TACT

Therapeutic angiogenesis by cell transplantation

TCP

Tissue culture plastic

TcPO2

Transcutaneous oxygen pressure

TGF-b1

Transforming growth factor beta-1

TGF-2

Transforming growth factor-2

TIMP

Tissue inhibitor of metalloproteinases

TNF-a

Tumour necrosis factor-alpha

TPO

Thrombopoietin

TSP-1,2

Thrombospondin-1 or -2

UCB

Umbilical cord blood

uPA

Plasminogen activator

v/v

Volume per volume

VCAM-1

Vascular cell adhesion protein-1

VE-cadherin

Vascular endothelial cadherin

VEGF

Vascular endothelial growth factor

VEGFR

Vascular endothelial growth factor receptor

vWF

von-Willebrand factor

xvi

Chapter 1

1

Introduction

1.1 Cardiovascular biology
The human body possesses a complex cardiovascular system consisting of the heart and
vascular network that delivers essential nutrients, maintains oxygen saturation and removes
waste products from metabolically active tissues. Oxygenated blood is delivered to all tissues
in the body through a dynamic vascular system consisting of an intricate hierarchy of
arteries, capillaries and veins.3, 4 The arterial and venous components of this vascular
hierarchy have a well-defined and unique histology made up of the tunica adventitia, tunica
media and tunica intima.3 The tunica adventitia is the outermost layer of the vessel that is
primarily composed of many fibro-elastic fibers that provide the vessel with structural
integrity and elasticity.5 The tunica media is the middle layer of the vessel that is comprised
of highly organized smooth muscle cells (SMCs) and elastin fibers.6 This region is
responsible for changes in vessel tone and plays an important role in regulating systemic
blood flow. The tunica intima consists of a single layer of luminal endothelial cells connected
to a structurally supportive basement membrane.7
Due to varying blood flow kinetics and the unique physiological roles of different blood
vessels, the cellular and molecular compositions of all three layers are histologically distinct
at each level of the vascular hierarchy. The aorta and large arteries contain greater amounts
of elastic tissue in the tunica adventitia to withstand the large changes in blood volume and
pressure delivered from the left ventricle.3 As these larger arteries bifurcate into smaller
arteries and arterioles, the muscular composition of the tunica media increases to moderate
the velocity of the blood and selectively divert it to fragile capillary beds.8 Returning to the
heart, deoxygenated blood passes through the capacitive venous system, characterized by the
presence of flow-directing valves and decreased fibro-connective and muscular tissue in the
tunica adventitia and tunica media, respectively.3

1.1.1

The endothelium

The endothelium is an interconnected single cell layer that lines the lumen of blood vessels
and is surrounded by stabilizing mural cells. Besides the endothelium’s fundamental role as
1

the interface between the blood and tissue compartments, it has also been shown to be
centrally involved in the regulation of circulatory hemodynamics through vessel-dependent
modifications in permeability, vasomotor tone and blood fluidity.9-11 Systemically, the
endothelium has also been shown to modulate the immune system through the upregulation
of cell adhesion molecules in response to inflammatory cytokines released by damaged
tissue.12 Adhesion molecules bind circulating monocytes and initiate a transmigratory
cascade that leads to the extravasation of monocytes into the extravascular space.13-15 Once
monocytes are recruited to the damaged tissue, they differentiate into macrophages and
dendritic cells that mediate the progression or resolution of tissue inflammation.16-18
There is substantial endothelial heterogeneity in the endothelial cell populations throughout
the vascular system that accommodate for the diverse roles the endothelium plays in a variety
of physiologic processes.19 In the arterial system, endothelial cells primarily act to regulate
blood flow and are structurally capable of withstanding high blood velocities and pressures.
In particular, endothelial cells in the arterial system are bound together by a higher frequency
of tight junctions and organize themselves along the longitudinal axis of the vessel.20, 21 To
mediate changes in vascular tone, endothelial cells actively communicate with smooth
muscle cells in the tunica media through a variety of secreted molecules and contactdependent signals.22, 23 Most prominently, endothelial cells demonstrate the capacity to
rapidly regulate vasomotor tone in response to high shear stress through nitric oxide (NO)
synthesis and release.10 In capillaries, the endothelium primarily facilitates the exchange of
oxygen, nutrients and metabolic waste between the blood and tissue compartments.24 Each
capillary is made up of a single layer of endothelial cells surrounded by a thin basement
membrane and specialized support cells, called pericytes.25 Pericytes function to regulate
capillary blood flow and guide endothelial cell differentiation and proliferation via gap
junction and paracrine signaling.25-27 Through reciprocal communication between the
endothelium and surrounding mural cells, vascular homeostasis is maintained in response to
changing hemodynamic and chemical signals. In the venous system, endothelial cells have
fewer tight junctions and predominantly function in leukocyte trafficking.28
In patients with chronic inflammatory diseases affecting the cardiovascular system, elevated
blood glucose and lipid levels promote systemic endothelial dysfunction via aberrant
signaling between the endothelium, hematopoietic cells and surrounding mural cells. As a
2

result, monocyte recruitment is accelerated, leading to the pathological accumulation of
monocyte-derived macrophages, release of pro-inflammatory cytokines and activation of
apoptotic cascades within the vessel wall.29

1.2 Cardiovascular disease
Cardiovascular disease (CVD) is a very common disease classification that encompasses a
wide range of pathologies affecting the heart and vascular system.30, 31 The most prominent
forms of CVD are ischemic heart disease, cerebrovascular disease, peripheral vascular
disease and hypertensive heart disease.31 Despite rapid improvements in prevention,
diagnosis and treatment, CVD remains the leading cause of premature death globally,
attributable to over 17 million deaths each year.31 This staggering number accounts for 31%
of the total global all-cause mortality and is forecasted to grow as CVD frequencies in low
and middle income countries increase at very high rates, despite decreases in frequencies
being recorded in higher income countries.31, 32 As a result, CVD places an immense burden
on national healthcare agencies and is estimated to comprise 17% of all medical expenditures
in the United States—a total of $270 billion per year.33, 34

1.2.1

Atherosclerosis

One of the defining etiologies responsible for CVDs is a chronic inflammatory condition
affecting blood vessels known as atherosclerosis.30, 31, 35 Atherosclerosis is characterized by
the chronic accumulation of lipid-laden plaque within the arterial intimal layer leading to
luminal narrowing of major arteries and drastic reductions in oxygen-rich blood flow to
target organs. In the most advanced and severe cases of atherosclerosis, fibrous plaques can
rupture and release prothrombotic material into the circulation. This material rapidly
coagulates to form an atherothrombotic blockage with the potential to travel distally before
lodging in a narrower vessel.35
Risk factors that contribute to atherogenesis within the arterial tree include dyslipidemia,
hypertension, inflammation, smoking, physical inactivity and diabetes.30, 35 Although the
exact mechanism regarding atherogenesis initiation remains controversial, it is suggested that
local hemodynamic forces play a crucial role following observations that atherosclerosis
predominantly occurs in arterial regions of where laminar flow is disrupted, such as branch
3

points and bifurcations.36 It is hypothesized that endothelial cells in these regions are affected
by low shear stress and perturbations in the laminar flow that result in poor endothelial cell
alignment, an increase in the endothelial layer permeability and alterations to the
subendothelial extracellular matrix (ECM).36-38
These modifications cumulatively lead to the subendothelial deposition of circulatory lowdensity lipoproteins (LDL) in the arterial intima layer.38 Following sustained LDL
deposition, the LDL particles are modified by myeloperoxidases or lipoxygenases released
from resident inflammatory cells, or oxidized by reactive oxygen species in the inflammatory
environment. Oxidized LDL particles aggregate together, forming an immunogenic material
that induces the release of inflammatory cytokines from tissue resident macrophages and
subsequently activates adjacent endothelial cells. Activated endothelial cells upregulate the
expression of adhesion molecules on the luminal surface, which attracts and binds circulating
leukocytes, such as monocytes and T-cells, facilitating migration into the vessel
intima.35, 39-41 Following migration, macrophages phagocytose the LDL particles present in
the intimal matrix and become lipid-laden foam cells.29
As macrophages and other immune cells continue to migrate into the lesion and amplify
lipoprotein retention, smooth muscle cells (SMC) from the tunica media migrate to the lesion
site, proliferate, and secrete large amounts of collagen and elastin to form a fibrous cap.42
Continued accumulation of LDL particles and mononuclear immune cells ultimately leads to
the formation of an inflammatory necrotic core, as macrophages become apoptotic and are
not effectively cleared from the plaque.29, 42, 43 Advanced atherogenic lesions (i.e. vulnerable
plaques) have the potential to undergo fibrous cap thinning and plaque rupture, leading to
acute atherothrombotic events such as myocardial infarction or stroke, or may progress into
stenoses that chronically reduce blood flow to downstream capillary beds.40

1.2.2

Peripheral artery disease

Peripheral artery disease (PAD) affects over 200 million people worldwide, and costs
national healthcare organizations billions of dollars annually.44-46 PAD is initiated by the
accumulation of atherosclerotic plaque in the peripheral arteries, with severe plaques causing
narrowing of the arteries and dramatic reductions in blood flow to the distal extremities.

4

Occlusions most frequently occur in the superficial femoral, iliac and/or tibialis posterior
arteries, reducing the supply of oxygen-rich blood to tissue downstream of the occlusion.47
Patients typically remain asymptomatic due to the extensive collateral vessel network in the
distal limbs, with symptoms only appearing when the reduction in collateral blood flow
surpass the oxygen demands of the downstream tissues.48 This typically occurs when luminal
occlusion exceeds 50% but varies among patients depending on the location of the plaque
and extent of vessel collateralization in the limb.48 As the luminal occlusion increases in size,
collateral arterioles dilate as a compensatory response to limb ischemia. For patients in the
end stages of PAD, arterioles are at the point of maximal dilation and are not able to respond
to further vasodilatory stimuli¾a phenomenon known as vasomotor paralysis.49, 50
Issues regulating vasomotor tone in primary feeder arteries lead to increased capillary
hydrostatic pressure that, in turn, promotes endothelial cell dysfunction, increased endothelial
permeability and edema.51 Additionally, endothelial cells in the ischemic environment
demonstrate increased leukocyte adhesivity leading to further release of pro-inflammatory
mediators, increased formation of reactive oxygen species (ROS) and improper platelet
activation.51, 52 As ROS accumulate in the calf muscle tissue, widespread ROS-induced
mitochondrial dysfunction leads to myocyte apoptosis, lipid accumulation, tissue fibrosis and
nerve damage.53-55 Overall, aberrant blood flow caused by the formation of atherosclerotic
plaques in larger arteries disturbs nutrient and oxygen transfer in capillaries, leading to
widespread inflammation, tissue necrosis, non-healing ulcers and gangrene.50
In the early stages of PAD, patients present with a myriad of mild symptoms including:
muscle pain with exercise (intermittent claudication), leg numbness, skin discolouration and
slow healing sores on the legs or feet.56 Individuals with larger, more diffuse occlusions in
feeder arteries suffer more severe limb ischemia, resting leg pain, gangrene and non-healing
ulcers and are typically diagnosed with the most serious form of PAD known as critical limb
ischemia (CLI).57 CLI is typically diagnosed through clinical examination of ulcers and
gangrene present on the affected limb and quantification of several objective measures of
hemodynamic perfusion, such as ankle brachial index (ABI) and transcutaneous oxygen
(TcPO2).58

5

With few effective treatment options available for CLI, up to 30% of patients will require
lower limb amputation in the first year due to extensive tissue necrosis and non-healing
ulcers.57, 59 More importantly, mortality rates are reported as high as 22% at 1 year post
diagnosis60, and quality of life scores for patients with no-option CLI are up to 2 standard
deviations below the general population in physical functioning and body pain
classifications.61 Diabetic patients typically experience more severe PAD, with amputation
and mortality rates being five-fold and two-fold higher, respectively.62 Unfortunately, the
prevalence of PAD and CLI is predicted to increase in the future due to the progressively
aging population and increasing prevalence of risk factors such as diabetes, hypertension and
obesity in the general population.63

1.2.3

Current treatments for PAD

The primary concerns relating to the treatment of PAD and CLI are due to asymptomatic
progression of the disease, and therefore, a lack of effective late-diagnosis treatment
options.64 According to the Trans-Atlantic Inter-Society Consensus for the Management of
Peripheral Arterial Disease (TASC II), the primary objectives for the treatment of CLI
include: relieving resting ischemic leg pain, prolonging amputation-free survival, increasing
ulcer healing rates, improving patient quality of life and reducing mortality.65 For most
patients with CLI, surgical revascularization procedures, endovascular catheterization and/or
pharmaceutical drug interventions are prioritized in an attempt to increase limb blood flow
and improve primary outcomes.65 While surgical and endovascular revascularization
procedures have been shown to modestly improve patient quality of life, amputation and
mortality rates remain high regardless of the surgical treatment intervention employed.66-69
Additionally, it is estimated that 50% of patients with CLI are not eligible for
revascularization procedures due to advanced comorbidities, and limb amputation is
frequently performed to prevent mortality and relieve the patient of severe symptoms.70
Overall, an effective therapy for the reversal of CLI and other atherosclerotic comorbidities
has remained elusive.71, 72

1.3 Mechanisms of vascular regeneration
In healthy individuals, vessel architecture and development is precisely regulated by the
oxygen demands of the downstream tissue capillary beds, with adaptive vessel remodeling
6

occurring on a continuous basis.73 For patients with PAD and other occlusive arterial
conditions, the delivery of oxygen-rich blood to distal capillary beds is impeded and the
metabolic demands of the tissues are not satisfied.50 As the disease progresses, the body
attempts to form new and remodel existing blood vessels through the three compensatory
mechanisms termed angiogenesis, vasculogenesis and arteriogenesis.4

1.3.1

Angiogenesis

Angiogenesis, first described by Judah Folkman in 1971, is broadly defined as the formation
of new capillary networks from pre-existing vessels.74 Angiogenesis encompasses two
complementary processes (intussusceptive and sprouting angiogenesis) that form new blood
vessels through distinct mechanisms. Intussusceptive angiogenesis is a dynamic process
mediated by the formation of transluminal pillars within small vessels and capillaries.75
These transluminal pillars will typically arrange in parallel along a vessel and will merge
together to create two separate vessels. Through repetition of this process, capillary networks
are able to undergo exponential multiplication and can form complex distal vascular trees—a
process known as intussusceptive arborization.76 Conversely, sprouting angiogenesis is the
budding and sprouting of endothelial cells from pre-existing vessels followed by continued
proliferation, migration and capillary stabilization.4
Angiogenesis is tightly controlled by the balance of stimulatory and inhibitory factors that
are present in a variety of physiological and pathological environments (Figure 1.1). Of the
stimulating factors, tissue hypoxia is the main driving force.24 In regions of tissue with low
oxygen concentrations, inflammatory and connective tissue cells signal regional hypoxia to
nearby vessels through the heightened activity of the heterodimeric transcription factor
hypoxia-inducible factor 1 (HIF-1).77 The HIF-1 transcription factor consists of constitutively
expressed HIF-1b subunit and an oxygen sensitive HIF-1a.78 Under normal oxygen tensions,
HIF-1a is continually synthesized and degraded based on the hydroxylation status of an
oxygen-dependent degradation domain. This domain consists of two proline residues that are
hydroxylated by HIF-1a prolyl hydroxylases using oxygen as a substrate.79 When these
proline residues are hydroxylated, the HIF-1a subunit is ubiquitinated and subjected to
degradation by the proteasome. In regions of hypoxia, HIF-1a prolyl hydroxylases become
inactivated due to a lack of oxygen and the proline residues on the HIF-1a subunit remain
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dehydroxylated. This increases the half-life of HIF-1a, allowing accumulation within the
cell.79 Accumulated HIF-1a dimerizes with constitutively expressed HIF-1b, leading to
translocation into the nucleus and DNA binding. Following binding to hypoxia response
elements, transcription of genes encoding a variety of proangiogenic cytokines including
VEGF, placental growth factor (PlGF) and the chemokine stromal derived growth factor-1
(SDF-1) are rapidly increased.4
Once the proangiogenic cytokines are produced and secreted, the factors bind to receptors on
nearby endothelial cells that ultimately results in destabilization of the pericyte-endothelial
cell layer and changes in vascular permeability.1, 80, 81 These changes are primarily mediated
by a fine balance between the VEGF/VEGFR and Angiopoietin-1(Ang1)/TIE2 signaling
axes, where overactivation of either pathway mediates the promotion or inhibition of
angiogenesis, respectively. While VEGF primarily acts to increase vessel permeability and
promote vessel sprouting, Ang1 acts in opposition to decrease vascular permeability through
the TIE2 receptor.82 In regions of vascular remodeling and angiogenesis, angiopoietin-2
(Ang2) is released and antagonizes Ang1 at the TIE2 receptor. When Ang2 is bound to the
TIE2 receptor, VEGF signaling predominates over Ang1, resulting in smooth muscle cell
detachment and increased vessel permeability.83 Simultaneously, disruptions of intracellular
vascular endothelial cadherin (VE-cadherin) and platelet endothelial cell adhesion molecule 1
(PECAM-1) junctions lead to the formation of fenestrations in the vessel wall and deposition
of plasma proteins such as fibrinogen and fibrin into the extravascular space. Migrating
endothelial cells use these extravasated plasma proteins as a temporary migration scaffold to
release a variety of proteolytic enzymes including matrix metalloproteinases (MMPs),
chymases84 and heparanases85 to degrade the surrounding basement membrane and progress
into the stroma.86 As the ECM is gradually degraded, matrix-bound growth factors such as
VEGF, basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1) and latent
transforming growth factor 2 (TGF-2) are liberated and act on sprouting endothelial cells to
guide vessel morphology.87, 88
Once the basement membrane surrounding the endothelial cells has been degraded, a single
endothelial cell adopts the tip cell phenotype.89 The tip cell is characterized by long, dynamic
filopodia that degrade the surrounding ECM and guide the sprouting vessel towards
angiogenic signals in the matrix.90 Behind the endothelial tip cell are many stalk cells that are
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phenotypically distinct from the tip cell. These stalk cells have fewer filopodia and rapidly
proliferate in response to VEGF.89 Initially, the stalk cells assemble as a solid cord and
subsequently form a lumen following vessel stabilization through upregulation of
intracellular adhesion molecules such as PECAM-1, various connexins and VE-cadherin.91, 92
As blood flow begins to exert shear forces on the nascent vessel, complementary platelet
derived growth factor (PDGF) and Ang1/TIE2 signaling completes the maturation of the
vessel through recruitment of pericytes and vascular SMCs that stabilize the vessel, stimulate
the production of ECM, reduce vessel permeability and induce endothelial cell
quiescence.93, 94

1.3.2

Vasculogenesis

Vasculogenesis is the de novo formation of new blood vessels from endothelial precursor
cells, a process first described in the developing embryo.95 In early embryogenesis, the
cardiovascular system is one of the first organ systems to form in order to supply developing
tissues with essential nutrients and oxygen.96 Following gastrulation, early mesodermal cells
migrate from the epiblast to the extra-embryonic endoderm through the primitive streak
where they form blood islands consisting of hematopoietic cells surrounded by a layer of
angioblasts. As blood islands develop, angioblasts differentiate into endothelial cells and
coalesce to form a vascular plexus. Further vessel development is mediated through
angiogenesis where new vessels bud and sprout from the existing plexus.95, 97
The vasculogenic process was believed to be exclusive to embryogenesis until circulating
bone-marrow derived endothelial precursor cells (EPC) were isolated from human peripheral
blood by Takayuki Asahara in 1997. 98 Due to the putative belief that endothelial cells and
hematopoietic cells arise from a common precursor, the hemangioblast, EPC were isolated
using the primitive hematopoietic cell surface antigens CD34 and the vascular endothelial
growth factor receptor (VEGFR), Flk1.98 Since then, there has been increasing evidence that
EPC participate in the neovascularization of damaged or injured tissues through a process
termed postnatal vasculogenesis.99, 100 Postnatal vasculogenesis occurs when EPC from the
bone marrow home to damaged tissues in response to hypoxia and other chemoattractants
such as: VEGF, granulocyte-monocyte colony stimulating factor (GM-CSF), fibroblast
growth factor-2 (FGF2), IGF-1 and SDF-1.1, 100, 101 Once the EPC have invaded the damaged
tissue, they form new vessel networks through differentiation into endothelial cells, paracrine
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modulation of pre-existing endothelial cells or direct inosculation into existing vessel
networks.102, 103

1.3.3

Arteriogenesis

While capillaries deliver small amounts of blood to individual cells, larger arteries facilitate
the systemic delivery of greater volumes of blood to many capillary beds throughout a vast
region of tissue. In the event of an arterial occlusion, such as PAD, bulk blood flow to a
tissue is reduced, leading to significant tissue ischemia.40 Due to redundancy present in the
vascular system, pre-existing low-flow collateral vessels feeding similar tissue regions are
actively remodeled and blood flow is diverted into these vessels to compensate for decreases
in perfusion caused by the occlusion.104, 105
This vascular remodeling occurs in response to increased flow velocity, and therefore fluid
shear stress, on endothelial cells within the collateral vessels.106 Endothelial cells in regions
of high shear stress take on an activated cell phenotype, associated with upregulated
expression of various adhesion proteins, including intracellular adhesion molecule-1 (ICAM1) and vascular cell adhesion protein-1 (VCAM-1), and release monocyte chemoattractant
protein-1 (MCP-1).107-109 Circulating monocytes bind to the endothelium and infiltrate into
the subendothelial space where they release a variety of growth factors, chemokines and
cytokines.109, 110 These proteins bind to surrounding endothelial cells and initiate their rapid
proliferation.106, 111 As the endothelial cells proliferate, they secrete other mitogenic factors
such as bFGF, PDGF and transforming growth factor beta-1 (TGF-b1) that subsequently
promote the rapid proliferation of the surrounding SMCs. Simultaneously, monocytes
produce proteinases, such as plasminogen activator (uPA) and MMPs, to proteolytically
break down the surrounding ECM to facilitate new vessel growth.112 In the final steps of
maturation, the SMC arrange in circular and longitudinal layers and deposit extracellular
elastin and collagen to support to the vessel.109 After remodeling, arteriogenesis can mediate
up to a 20-fold increase in vessel diameter, leading to increased blood flow to downstream
tissues within weeks of vessel

occlusion.113, 114
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Figure 1.1 Mechanisms of vascular regeneration. Existing blood vessels can be remodeled
or new blood vessels can be formed at varying levels of the vascular hierarchy through three
complementary processes. Angiogenesis, the formation of new capillary networks from preexisting vessels through sprouting or intussusception; Vasculogenesis, the de novo formation
of new blood vessels from endothelial precursor cells; and Arteriogenesis, the dynamic
remodeling of pre-existing collateral vessels.1 All acronyms are defined in the main text.
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1.4 Hematopoietic stem and progenitor cells
1.4.1

Hematopoietic stem cell development and role in hematopoiesis

Hematopoietic stem cells (HSC) are extremely rare, pro-regenerative cells responsible for the
derivation of all blood cells over the course of an organism’s lifetime (Figure 1.2). HSC are
characterized by their ability to differentiate into all cells in the myeloid and lymphoid
lineages and their capacity to self-renew for maintenance and/or expansion of the progenitor
cell pool.115-117 Hematopoiesis is separated into two developmental waves¾called primitive
and definitive hematopoiesis¾that serve similar yet distinct functions for the developing
embryo.118 During early embryo development, primitive hematopoiesis first occurs through
HSC emerging from blood islands in the yolk sac.119 Their purpose is to contribute towards
the earliest forms of erythropoiesis to supply the growing embryo with red blood cells (RBC)
for transient tissue oxygenation.120 Definitive hematopoiesis occurs at a later timepoint and
accounts for the production and homeostasis of all mature cell types in the blood throughout
life. HSC responsible for definitive hematopoiesis first emerge in the aorta-gonadmesonephros (AGM) region before migrating to the fetal liver and bone marrow in the third
trimester.121
In the bone marrow, HSC reside in a quiescent state within the endosteal niche surrounded by
supportive perivascular stromal cells and vascular endothelial cells.122-124 The complex
physical, cellular and chemical components of the bone marrow microenvironment have been
highly studied and play an important role in the maintenance of the progenitor cell pool and
coordinate the generation of a hematopoietic hierarchy.122 During development, quiescent
HSC (termed long-term HSC or LT-HSC) are believed to give rise to phenotypically distinct
short-term HSC (ST-HSC) that have a limited capacity for self-renewal. These ST-HSCs
generate multipotent progenitor cell (MPC) populations that develop into lineage-committed
progenitors and subsequent mature cells of the lymphoid (e.g. NK, B and T cells), myeloid
(e.g. granulocytic and monocytic/macrophage cells) and megakaryo-erythroid (e.g.
megakaryocytes, platelets and erythrocytes) lineages (Figure 1.2).125
During adult life, LT-HSC are believed to contribute less to steady-state hematopoiesis, with
ST-HSC being the driving force behind the derivation of mature hematopoietic cell types.126
However, in response to hematopoietic stressors that deplete mature hematopoietic cell
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populations, such as systemic infection127, it has been suggested that LT-HSC exit out of
their quiescent state in response to interferon signaling and produce myeloid and lymphoid
progenitors that facilitate the replacement of depleted progenitor cell populations and restore
hematopoietic homeostasis over time.128

1.4.2

Hematopoietic stem and progenitor cell isolation and
characterization

The discovery of HSC by stem cell pioneers Drs. James Till and Ernest McCulloch was
documented in early bone marrow transplantation studies involving lethally irradiated
mice.115-117 Drs. Till and McCulloch observed that mice subjected to lethal irradiation would
survive if they received a syngeneic bone marrow transplant from a non-irradiated animal.
Following the discovery of donor-derived clonogenic colonies in the spleen of recipient
animals, they postulated that there were multipotent cells present in the bone marrow that
were capable of reconstituting the entire hematopoietic system and maintaining
hematopoiesis (Figure 1.2).115-117
Since then, prominent research groups around the world have dedicated their life’s work to
the isolation and characterization of these rare cell populations in the murine and human
hematopoietic systems. Early attempts to purify murine HSC using density gradients, antimitotic agents and surface glycoprotein molecules demonstrated success in enriching
multipotent hematopoietic progenitor cells but lacked the ability to distinguish between cells
that were able to self-renew and cells that were more committed.129, 130 It wasn’t until 1975,
when Georges Köhler and César Milstein demonstrated the groundbreaking ability to
formulate and purify monoclonal antibodies,131 that researchers were able to characterize the
cell surface antigens exclusively found on primitive and mature cell populations in the
hematopoietic system and enabled the field to identify hematopoietic stem cells capable of
self-renewal.132
In humans, hematopoietic stem and progenitor cells (HSPC) can be derived abundantly from
umbilical cord blood (UCB) 133 and bone marrow134, but can be also found to a lesser extent
in peripheral blood.135 Traditional isolation of HSPC has focused on the positive and negative
expression of various cell surface markers, with more stringent panels involving multiple cell
surface markers being required for the isolation of the extremely rare LT-HSC capable of
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self-renewal. The first cell surface marker found to be highly expressed on HSC was CD34,
but elevated expression was also exhibited on more committed hematopoietic progenitor
cells (HPC).136 This finding led researchers to search for additional cell surface markers that
would allow for the removal of differentiated cell types and enable enrichment of the most
primitive HSC population. Presently, after decades of research, the most agreed upon cell
surface marker phenotype for HSC at the top of the hematopoietic hierarchy is a cell that is
depleted of mature hematopoietic populations (lineage-depleted) and is
CD34+CD90+CD45R-CD38-.134, 137-139 Otherwise, purification performed on lineage-depleted
cells based on CD34+CD133+ or CD34+CD38- expression has been shown to broadly select
for a mixture of both HSC and HPC with moderate long-term hematopoietic reconstitution
capacity in immunodeficient mice.134, 140
Paradoxically, there has also been recent evidence showing that there is an extremely small
population of quiescent LT-HSC at the top of the hematopoietic hierarchy that are
Lin−CD34−CD38−CD93hi and may upregulate CD34 expression following early HSC
differentiation.141 Due to the transient expression of many cell surface markers and the need
for complex immunological stains, recent findings suggest that use of functional markers
such as aldehyde dehydrogenase (ALDH) activity may also be effective at isolating
progenitor cells from heterogeneous cell populations based on a primitive cell function rather
than cell surface phenotype.133, 142
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Figure 1.2 Overview of human hematopoietic hierarchy. Long-term hematopoietic stem
cells are at the top of the hierarchy and give rise to all mature hematopoietic cell populations in
the myeloid and lymphoid lineages. MEP: Megakaryo-erythroid progenitor, LT-HSC: Longterm hematopoietic stem cell, ST-HSC: Short-term hematopoietic stem cell.
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1.4.3

Aldehyde dehydrogenase

The ALDH enzyme superfamily consists of 19 distinct isoforms organized into 11 families
and 4 subfamilies with varying substrate specificity and tissue distribution.143, 144 Different
isoforms of ALDH are found throughout the cytosol, mitochondria, nucleus and endoplasmic
reticulum, and are believed to play an important cytoprotective role by catalyzing the
oxidation of reactive aldehydes from endogenous and exogenous sources to less toxic
carboxylic acids.145 Aldehydes are electrophilic compounds that have the potential to
covalently bond with nucleophilic compounds such as DNA, enzymes, structural proteins
and other macromolecules. Through the covalent bonding to cellular components, reactive
aldehydes can extensively damage intracellular components leading to downstream
mutagenic, cytotoxic and carcinogenic effects.146 Exogenous aldehydes can be derived from
environmental sources (i.e. cigarette smoke, industrial manufacturing, air and water
pollution), but are also formed following the ingestion of xenobiotics, food and drugs (i.e.
ethanol and anti-cancer drug cyclophosphamide).147, 148 Endogenous aldehydes are formed as
biproducts of many physiological processes involving the metabolism of lipids (i.e. lipid
peroxidation), amino acids, carbohydrates and vitamins.145, 149
Besides their ubiquitous role in the reduction of the cytotoxic effects of reactive aldehyde
species, ALDH enzymes are also crucial for guiding differentiation during embryogenesis
and are commonly upregulated in multiple stem cell and cancer stem cell populations.150-153
In stem cells, the ALDH1A1 and ALDH3A1 isoforms have demonstrated particular
importance towards self-protection, differentiation and self-renewal.154, 155 The protective
function of both of these isoforms can be seen through their contributions towards mediating
increased resistance for HSPC against alkylating agents such as cyclophosphamide.154 As for
the regulation of differentiation and self-renewal in stem cell populations, ALDH1 isoforms
(i.e. ALDH1A1, ALDH1A2 and ALDH1A3) are the rate-limiting enzyme for the multi-step,
intracellular conversion of retinol (vitamin A) to retinoic acid.156 Retinoic acid is produced
through the reversible oxidation of retinol to retinaldehyde by retinoid dehydrogenases
followed by irreversible oxidation of retinaldehyde to retinoic acid by cytosolic ALDH1A
isoforms.157 Retinoic acid is a potent morphogen and stimulates cell differentiation through
its activation of the retinoic acid receptor/retinoid X receptor (RAR/RXR) transcription
factor complex.157, 158 These morphogenic effects can be measured through experiments
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inhibiting retinoic acid production through the use of reversible ALDH-inhibitors such as
diethylaminobenzaldehyde (DEAB). Specifically, studies have found that HSC demonstrated
blunted differentiation when cultured with DEAB in vitro, leading to the amplification of
HSC capable of self-renewal when measured in reconstitution assays in non-obese
diabetic/severe combined immune deficient (NOD/SCID) mice.158 Overall, stem cells must
maintain a complex balance between ALDH-induced retinoid signaling and retinoic acidinduced differentiation to ensure the production of mature blood cells without depletion of
the stem cell pool.

1.4.4

Aldehyde dehydrogenase as an alternative marker for
progenitor cell populations

One benefit to elevated ALDH-activity present in stem and progenitor cells is that it can be
used to purify primitive cells based on cell function rather than cell surface phenotype.
Within the hematopoietic hierarchy, ALDH-activity is reduced as HSC differentiate towards
a mature state. Differential expression of ALDH1 among HSC and more committed lineages
was first demonstrated in 1990 using flow cytometry with conjugated antibodies that bound
to intracellular isoforms of ALDH1 and various cell surface markers.159 This study found that
CD34+ hematopoietic cells also demonstrated elevated ALDH1 levels compared to mature B,
T and monocytic cells.159
While these studies were effective in characterizing ALDH expression within the
hematopoietic hierarchy, the cells needed to be fixed and permeabilized prior to analysis and
therefore had limited clinical applicability. Five years later, Jones et al. developed the first
flow cytometric assay for ALDH activity that could be used on viable cells using the
fluorescent substrate of ALDH, termed dansyl aminoacetaldehyde (DAAA).160
Unfortunately, due to the polarity of the fluorescent molecule produced following oxidation
by ALDH1, the substrate would remain in the isolated cells indefinitely, thus leading to
mutagenic consequences and limiting clinical applications.142 To address this drawback with
(DAAA), Storms et al. developed a new fluorescent substrate for ALDH, BODIPYaminoacetaldehyde (BAAA), that could be washed out of cells following fluorescence
activated cell sorting (FACS).142 Using this assay, isolation of viable human HSPC from
bone marrow, umbilical cord blood and peripheral blood were successfully employed in
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regenerative medicine applications in animal models of hematopoietic reconstitution, acute
myocardial infarction, liver damage and limb ischemia.161-163
ALDH-activity was not only successful in purifying hematopoietic cells with a primitive
phenotype but could also be used to isolate endothelial precursor cells and multipotent
mesenchymal stromal cell (MSC) populations that could act in concert with host-derived
cells to accelerate blood vessel regeneration.163-166 In mice with femoral artery ligation
(FAL), intravenous (IV) or intramuscular (IM) injection of UCB-derived ALDHhi cells
significantly restored limb perfusion up to day 35, despite limited cell engraftment and
transient survival in the ischemic muscle (<7 days).165 It was believed that their enhanced
regenerative capacity was mediated through the secretion of various pro-angiogenic paracrine
signals, including VEGF, interleukin-8 (IL-8), Ang1 and fibroblast growth factor 16 (FGF16), that collectively induced small collateral vessel formation to restore blood flow in the
ischemic limb.165 Mounting preclinical evidence of the regenerative capacity of human HSPC
derived from BM or umbilical cord blood in mouse models of limb ischemia has led
researchers to propose that HSPC transfer may improve patient outcomes for occlusive
arterial diseases such as PAD.

1.4.5

Alternative revascularization strategies for patients with PAD

As mentioned previously, therapeutic interventions for PAD are targeted at relieving the
severe symptomology of the disease, reducing amputation rates, improving patient quality of
life and reducing patient mortality.65 Patients with severe CLI that do not qualify for
traditional surgical revascularization techniques have limited treatment options to reduce
symptoms, reestablish distal blood flow and restore metabolic homeostasis to the ischemic
limb. As such, early attempts to stimulate revascularization involved systemic delivery of
potent regulators of angiogenesis to restore blood flow and improve patient symptoms.

1.4.5.1

Recombinant proteins for stimulating angiogenesis

Alongside the discovery of many of the mediators of angiogenesis, such as VEGF, FGF and
hepatocyte growth factor (HGF), researchers initially attempted to stimulate therapeutic
angiogenesis through the intra-arterial administration of pro-angiogenic recombinant
proteins.167, 168 While the administration of recombinant VEGF or FGF successfully
stimulated collateral remodeling, increased capillary density and restored hemodynamic
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deficits in animals with unilateral hindlimb ischemia, questions were raised regarding the
clinical applicability of recombinant protein administration in human subjects with
PAD.168, 169
First, due to the drastic size differences between the animals used to test the efficacy of the
proangiogenic recombinant proteins and human subjects, an extensive scale-up and good
manufacturing practices (GMP) overhaul of the expensive recombinant protein
manufacturing process would be needed to achieve quantities of protein required for human
administration. Secondly, continuous intravascular (IV) or intramuscular (IM) administration
of proangiogenic growth factors would be needed to achieve therapeutic benefit due to the
short plasma half-life (e.g. 33.7 minutes for VEGF) and susceptibility to degradation.170 In
studies exploring collateral remodeling with recombinant VEGF in canine models of
myocardial infarction, daily administration of VEGF into the coronary arteries was required
to improve collateral coronary blood flow and intramyocardial vessel density.171
Furthermore, IM and IV routes of administration would be unable to prevent the systemic
effects of the growth factors and would likely lead to undesirable side effect profiles.

1.4.5.2

Gene therapies approaches for the treatment of PAD

To address some of the shortcomings and safety concerns with the use of recombinant
proteins for therapeutic angiogenesis, gene therapies encoding angiogenic growth factors
were developed. Gene therapy involves the transfer of genetic material though plasmids, viral
vector systems or liposomal complexes for a therapeutically beneficial effect.172 Cells that
are successfully transfected with plasmids or transduced with viral vectors demonstrate
increased expression of the transferred gene leading to augmented expression and secretion
of the angiogenic growth factor. Gene therapies were predicted to be a safer and more
efficacious alternative to recombinant protein therapies due to the potential to achieve a local
and sustained release of pro-vascular growth factors to mediate therapeutic angiogenesis.
Similar to recombinant protein studies, researchers demonstrated that the transfection of
individual mediators of angiogenesis, such as VEGF,173 FGF174 and HGF,175 into animals
with surgically-induced hindlimb ischemia effectively stimulated angiogenesis, promoted
collateral development and improved limb perfusion. Despite promising results in preclinical
studies, gene therapies modulating VEGF, FGF or HGF expression in phase II and III
19

randomized clinical trials demonstrated minimal improvements to primary endpoints (limb
salvage) and were deemed therapeutically ineffective in patients with CLI.176-182 It was
believed that translational failure of these gene therapies could be attributed to issues with
delivery of the gene to the target tissue, low gene-transfer efficacy and variable or transient
expression of the transferred gene.183 Additionally, others have postulated that gene therapies
targeting a single growth factor in the extremely complex angiogenic cascade, involving
hundreds of cues from several distinct cell populations and the ECM, may not be sufficient to
stimulate angiogenesis in the face of advanced cardiovascular pathologies.176 Thus, there
remains an unmet need for a therapeutic strategy that stimulates angiogenesis using multiple
angiogenic factors, is safely administered and effective at improving primary endpoints (i.e.
amputation free survival and patient mortality) for patients with CLI.

1.4.5.3

Cell-based therapies for the treatment of PAD

Novel therapies harnessing the robust angiogenic secretome of adult stem cells to stimulate
therapeutic angiogenesis have been at the forefront of regenerative medicine for CLI.184
Historically, the use of adult stem cells for initiating therapeutic angiogenesis began with the
discovery of EPC.98 Indeed, these cells were capable of contributing to post-natal
neovascularization following IV injection into athymic mice with surgically-induced
hindlimb ischemia. While the functional neovascularization capacity of the purified EPC was
evident in the animal studies, the ‘EPC’ nomenclature given to this population was inaccurate
due to co-expression of these markers on progenitors within the hematopoietic lineage.185
Later studies characterizing EPC defined by Asahara et al. found that there were distinct
hematopoietic and endothelial progenitors capable of supporting the formation of new
vessels through angiogenic cytokine secretion and by structural vessel incorporation,
respectively.185, 186 Although extremely rare, these cell populations predominantly reside in
the bone marrow and can mobilize into the peripheral circulation in response to stimuli such
as growth factors, tissue damage and hypoxia.187 Therefore, researchers postulated that both
of these extremely rare regenerative cell populations could be harvested from easily
accessible sources, such as peripheral blood, bone marrow and umbilical cord blood, and
injected into damaged tissue to accelerate therapeutic neovascularization. Early
transplantation studies in rabbits started with the autologous use of unselected mononuclear
cells derived from the bone marrow (BM-MNC) for the treatment of surgically-induced
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hindlimb ischemia.188 This study found that transplanted cells incorporated into the capillary
network, induced collateral vessel formation, increased capillary density and increased limb
perfusion relative to saline controls.188
Based on these successes stimulating limb revascularization in animal models of CLI, the
first randomized clinical trial involving the autologous transplantation of BM-MNC was the
Therapeutic Angiogenesis by Cell Transplantation (TACT) trial reported in 2002.189 For
patients with unilateral and bilateral CLI receiving autologous BM-MNC, improvements in
ABI, TcPO2, and pain free walking time were demonstrated at the 4 week timepoint and
sustained for up to 24 weeks. Furthermore, long term follow-up on patients receiving the
BM-MNC showed maintained improvements in leg pain, ulcer size and pain free walking
time at 3 years post-therapy.190
While the therapeutic benefit of BM-MNC was demonstrated, subsequent studies claimed
that BM-MNC were only partially effective improving patient prognosis, as amputation and
mortality rates remained unchanged following treatment.191, 192 A meta-analysis, completed
in 2010 by Weem et al. of 10 randomized controlled trials (RCT) exploring the
proangiogenic and regenerative abilities of transplanted autologous mononuclear cells for
CLI showed no improvement in amputation, survival and ulcer healing rates for trial
participants.193 Conversely, a more recent meta-analysis including 19 RCT completed over
the last two decades concluded that autologous MNC effectively reduced the risk of major
amputation by 37%, improved amputation free survival by 18% and improved wound healing
by 59%.194 Overall, the ability of unselected autologous MNC to reduce primary endpoints
such as amputation rates and patient mortality remains controversial, and despite
improvements in various secondary endpoints such as ABI, TcPO2 and leg pain, a successful
phase III/IV trial for limb ischemia has remained elusive.
Unselected BM-MNC represent an extremely heterogeneous cell population consisting
primarily (>90%) of mature hematopoietic cells with infrequent representation by HSPC,
EPC, and stromal cells.99 While there have been studies demonstrating the regenerative
capacity of mature hematopoietic cell lineages, such as monocytes and macrophages, it has
been hypothesized that BM-MNC only contain a small fraction of cells capable of effectively
stimulating therapeutic angiogenesis.195 Further refinement of cell-based approaches using a
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more homogenous proangiogenic cell population is warranted to bolster the therapeutic
capabilities of injected cells and may lead to better outcomes when translated to RCT.
Supporting this theory, cell selection using primitive cell surface markers CD34 and Flk-1
effectively enhanced collateralization and capillarization in the ischemic limbs of mice with
surgically induced hindlimb ischemia, leading to hemodynamic recovery and improvements
in myofiber regeneration.196 When these findings were translated into human studies
involving CD34+ cells derived from the blood following BM-MNC mobilization with GFCSF, changes in amputation rates trended towards high-dose CD34+ cell therapy versus
saline controls but ultimately failed to reach significance (p = 0.06).197 Other studies using
functional markers (i.e. ALDH activity) also demonstrated success stimulating limb
vascularization and increasing perfusion in preclinical animal models of CLI when injected
IV163. However, when translated into humans, autologous ALDHhi cells derived from bone
marrow demonstrated modest clinical benefit in improving ABI at the 6 and 12 week
timepoints but did not improve overall amputation rates compared to unselected BMMNC.198 Thus, following two decades of preclinical and clinical experimentation involving
the use of selected and unselected MNC from the bone marrow or peripheral blood, there still
remains a need to develop an improved cell therapy able to reduce amputation rates and
mortality in patients with CLI.

1.4.5.4

Limitations of cell-based revascularization strategies for PAD

It is evident in most preclinical and clinical studies completed to date that MNC derived from
the bone marrow, peripheral blood or umbilical blood show some therapeutic efficacy,
despite not being able to reduce amputation rates in large RCT. While some of these
difficulties can be attributed to the lack of large animal models with atherosclerosis-induced
CLI to test therapeutic approaches,199 there are several fundamental limitations in current
therapies that need to be addressed to improve the therapeutic benefit of cell therapy.
First, the majority of proposed therapies involved the use of autologous cell populations
where the proangiogenic fraction of the isolated cells remained extremely
low (<1%).188, 189, 192, 194, 197, 198 To account for these low frequencies, many studies
compensated by using large cell dosages requiring extensive tissue harvesting. The TACT
trial alone required 500 mL of aspirated marrow per patient; an amount that makes up almost
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a third of the total marrow volume (1.75 L) of a 70 kg adult.200 In a meta-analysis of 37
studies involving autologous injection of BM-MNC completed by Fadini et al., an average of
3.56 ± 2.81 × 109 unselected MNC and 5.0 ± 1.48 × 107 CD34+ cells were injected per
patient.201 While these methods of tissue harvesting and cell purification are feasible in
smaller clinical trials, scaling up to millions of PAD patients would place a significant cost
and time burden on the healthcare system.
To address these limitations, scalable allogeneic sources of purified proangiogenic cells
could be further developed for an ‘off-the-shelf’ solution to CLI. UCB represents an easily
accessible and routinely discarded MNC source enriched for proangiogenic cell populations,
as shown through the successful derivation of HSC202, EPC203 and MSC204 for downstream
applications. The drawback to UCB is that only small volumes of blood (<100 mL) can be
obtained from each sample. To obtain sufficient numbers of cells for therapeutic purposes,
researchers have developed clinically relevant serum- and xeno-free ex vivo expansion
protocols to scale up the number of cells available for injection.164, 205 Unfortunately, a caveat
to this approach is that the cells may lose their regenerative potential during culture.164 To
ensure effective scale-up while minimizing loss of regenerative function, several groups have
investigated the use of pharmacological agents to try to maintain cells in their primitive
state.158, 206
The use of cells from an allogeneic source also addresses limitations using autologous cells
taken from an advanced pathological environment. It is becoming more apparent that
systemic inflammation, hyperglycemia and hyperlipidemia associated with diabetes and
atherosclerotic cardiovascular sequelae result in dysfunction of circulating EPC via
accelerated aging and senescence.207, 208 Furthermore, measurement of circulating EPC has
been used as a metric for the diagnosis of vascular co-morbidity as diabetic patients with
PAD demonstrated significant reductions in circulating EPC (i.e CD34+CD133+KDR+ cells)
compared to non-PAD patients.208 Thus, translation of novel cell therapies involving purified
cells from an allogeneic source may provide improved patient outcomes due to a lack of
impairment from chronic diabetes and atherosclerosis related co-morbidities.
Finally, many cell therapies, including those for CLI suffer from a lack of cell survival and
retention at the ischemic site following IV- or IM-injection. In a study using IV injection of
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BM-MNC or ALDHhi MNC into immunodeficient mice, cells were rarely found remaining in
the ischemic tissue past day 7 post-transplantation, but were frequently detected in the bone
marrow when analyzed by flow cytometry.165 This lack of human cell engraftment limits
capacity of the delivered cells to exert pro-vascular paracrine effects on damaged tissues,
which may impede functional revascularization. To account for this, many researchers are
beginning to explore multidisciplinary approaches to improve cell engraftment and retention
to prolong paracrine functionality of therapeutic cell populations.209

1.5 The use of biomaterials as a cell delivery platform
Biomaterial-based regenerative medicine approaches for the treatment CVD have been under
investigation since the early 2000s, with early studies employing injectable biopolymers for
cell delivery in animal models of myocardial infarction.210, 211 Since then, there has been
growing interest in the development of novel cell delivery strategies utilizing natural (e.g.
collagen212, hyaluronic acid213, alginate214 and decellularized tissue ECM215) and synthetic
(e.g. polymer216 or peptide217) biomaterials to successfully stimulate therapeutic angiogenesis
in patients with PAD. Before discussing the pros and cons associated with the use of
biomaterials, it is important to understand the structure and function of the ECM that
provides the native microenvironment for peripheral blood vessels.

1.5.1
1.5.1.1

The extracellular matrix
ECM function

The ECM can be broadly defined as the acellular 3D compartment within human tissues that
functions as a structural framework and provides essential biochemical and biomechanical
cues that direct cell differentiation, proliferation, migration and survival.218 The ECM is
composed of a complex mixture of proteins and polysaccharides that demonstrate tissuedependent physical and biochemical characteristics.219 The unique biochemical composition
of the ECM in different tissues is a by-product of the dynamic and reciprocal communication
between the cells and the matrix constituents.
While the structure and composition of the ECM is varied among diverse tissue types in the
body, the general functions of the ECM are similar and can be broadly classified into 4
different categories. First, the ECM provides cells with a structural scaffolding system for
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cell adhesion and migration.220 Second, the structural integrity of all tissues is reliant on the
composition of the ECM, with different tissues expressing predefined frequencies of proteins
with variable biomechanical properties in accordance with the tissue’s location and primary
function.221 Third, the matrix microenvironment contains hundreds of bioactive cues that
instruct cell behavior. Most prominently, cells partake in bidirectional mechano-transduction
cell signaling through integrin proteins in the cell membrane. Integrins are heterodimeric
proteins made up of different a and b subunits that bind to unique protein sites present in the
ECM. Depending on the specific heterodimer bound, cells directly link their cytoskeleton to
the surrounding matrix and activate various intracellular signaling pathways.222 Finally, ECM
provides a dynamic environment that cells can remodel in response to developmental,
homeostatic and pathological cues.223 How each of these functions relates to specific
molecular and biological components of the ECM will be discussed in more detail below.

1.5.1.2

ECM architecture and composition

In general, within tissues, the ECM is organized into two distinct forms that differ in their
biochemical composition and function. First, the basement membrane (BM) is a thin, fibrous
layer of ECM proteins that acts of a point of attachment for monolayers of endothelial or
epithelial cells and serves as a physical barrier from adjacent connective tissues. BMs
provide structural support to cell monolayers and communicate extensively with cells in the
adjacent stroma.224 Second, the interstitial matrix is comprised of ECM proteins that are
heavily secreted by fibroblasts in the stroma and function to define the 3D tissue structure.225
ECM proteins can be discriminated from one another based on their function, with large
fibrous proteins (i.e. collagens and elastins) playing predominant structural roles and smaller
glycoproteins (i.e. fibronectins, laminins and tenascins) exhibiting functional influences on
cell behaviour.225 Of the structural ECM proteins, collagen is the most abundant, and acts to
provide mechanical integrity to tissues and to facilitate cell adhesion and migration.225 There
have been 29 different proteins identified in the collagen family to date, which can be
categorized based on their ability to form structural fibrils (i.e. type I, II, III, V and XI) or
sheet-like basement membranes (i.e. type IV).226 While the collagen composition differs
between tissues, collagen types I, II and III are the most prevalent and together make up 80 90% of total collagen in the body.226 Collagen possesses a high degree of stiffness and
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functions in concert with other structural ECM proteins to provide the overall biomechanical
properties required within tissues. In tissues that need to be able to recoil following
stretching, such as tendons or blood vessels, collagen fibers are typically integrated with
small amounts of elastin proteins that impart tissue elasticity.227
While both collagen and elastin are important for the structural integrity of the ECM, other
proteins and proteoglycans bound to the structural matrix provide cues that mediate cell
migration, proliferation and adhesion.228 For example, fibronectin is a fibrillar protein known
for pleiotropic effects on cell behaviour and as an important regulator of adhesion dependent
cell growth.229 Proteoglycans represent another group of important ECM molecules that
consist of a protein core (with the exception of hyaluronic acid) and branching
glycosaminoglycan (GAG) chains.228 Within the interstitial space, proteoglycans and GAGs
play a role in tissue hydration, structural ECM assembly, and modulation of cell behavior
through regulation of cytokine and growth factor signaling.228 Other important components
of the ECM include sequestered MMPs, cytokines and growth factors released following
ECM remodeling, including during angiogenesis and wound healing.230 Overall, the ECM is
an incredibly complex environment that provides precise biochemical and biophysical
signaling to ensure proper cell differentiation, migration, proliferation and survival. By
mimicking traits of the ECM, researchers may be able to direct cell behaviors through the
careful design of 3D biomaterials for therapeutic intervention.

1.5.2

Biomaterial requirements

Optimally, engineered biomaterials should mimic the biophysical and biochemical traits of
the native tissue target sites in the body. However, due to the highly complex nature of the
native ECM and dynamic interactions between cellular constituents and matrix proteins, it is
extremely difficult to recapitulate exact microenvironments found in the body. For this
reason, bioengineers must consider the specific physical, mechanical, and chemical
characteristics of the native tissue needed for the intended application.
For biomaterials to be effective in cell delivery strategies for PAD, they need to facilitate
sustained release of proangiogenic factors from transplanted cells for prolonged therapeutic
benefit. As such, the implanted biomaterials should provide a microenvironment that
supports cell survival and retention at the site of transplantation despite tissue ischemia and
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degeneration.231 Importantly, biomaterials should not induce a chronic inflammatory or
immunological response when transplanted into the host. Thus, the derivation of the
biomaterial and all steps of the manufacturing process need to be regulated to reduce the
retention of toxic and pathogenic substances.232
To facilitate tissue integration, the biomaterial must be structurally and biomechanically
compatible with the transplant site. Furthermore, scaffolds need to demonstrate architectural
features that permit tissue remodeling and host integration, while providing mechanical
support as regeneration progresses. Physical characteristics such as porosity and substrate
stiffness must be fine-tuned to ensure cells are able to adhere and migrate within the
matrix.233 Biomaterials can also be actively remodeled by host cells to permit vascularization
within the constructs, which is necessary for the transport of essential nutrients to the
delivered and infiltrating cell populations. Finally, while not critical to the success of the
engineered scaffolds, functional bioactivity mediated through sequestered growth factors and
cytokines, such as VEGF and Ang-1, may support rapid scaffold vascularization and
contribute to cell patterning for additional therapeutic benefit.234, 235 While many engineers
focus on the creation of synthetically derived biomaterials that recapitulate features of native
tissues, biomaterials derived from decellularized tissues have innate bioactivity and can more
closely replicate the native cellular microenvironment.236 This may be favorable for
therapeutic efficacy, while remaining clinically applicable due to low immunogenicity and
ease of production.236, 237

1.5.3

Decellularized tissue biomaterials

Protocols for the decellularization of intact tissues and organs have been an area of intense
investigation in tissue engineering. The methodologies used to decellularize tissues vary
widely among studies but generally involve a sequential process with physical (i.e.
freeze/thaw cycles, sonication or tissue agitation), chemical (i.e. ionic solutions and
detergents) and/or enzymatic (i.e. trypsin and nucleases) treatments.237 Intuitively, harsher
processing steps involving the use of detergents to remove cells may result in extensive
damage to the native ECM through reductions in GAGs and sequestered growth factors.238
Therefore, the primary goal of the tissue decellularization process is to remove immunogenic
cellular components from the tissue using milder reagents while retaining the overall
composition, bioactivity and physical integrity of the native ECM as much as possible.236
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Over the past few decades, several decellularized tissue scaffolds have been successfully
used in pre-clinical studies and progressed to clinical trials for a wide range of clinical
indications.239-241 To date, decellularized constructs have been derived from many tissues
including the cornea242, esophagus243, heart valve244, blood vessels245, skin246 and skeletal
muscle.247 While the decellularization of many of these tissues is feasible in a research
setting where only small amounts of tissue are needed, the clinical applicability of
biomaterials derived from human tissues that are difficult to procure (e.g. heart valve and
cornea) remains a challenge. Many researchers have successfully derived decellularized
tissue from widely available xenogeneic sources, selected based on the high degree of
conservation of ECM proteins between different species.248 While these implants are
typically well tolerated, the use of xenogeneic material in the clinical setting is complicated
by the potential risk of xenozoonosis.249 Therefore, there is a need for human decellularized
matrices that are abundantly available and capable of supporting integrated cells to stimulate
in situ regeneration.

1.5.4

Adipose tissue derived biomaterials

Human adipose tissue (fat) is a highly-specialized connective tissue that is ubiquitously
found throughout the body. In addition to cushioning organs and providing insulation, it also
serves as a dynamic energy reservoir through the storage of triglycerides in adipocytes.250
Other important cell types present in fat are adipocyte precursors, stromal cells, endothelial
cells, smooth muscle cells and immune cells, including tissue resident macrophages.251 These
stromal-vascular cell populations are associated with the extensive vascularization of the
tissue needed to support adipogenesis and can contribute to the tissue structure through the
deposition of ECM proteins.252, 253 Of these proteins, adipose tissue ECM has been found to
be a rich source of proteins including collagen types I – VI, fibronectin and laminin, and
contains a variety of growth factors that are associated with adipogenesis and
angiogenesis.254, 255 For these reasons, it has been proposed that adipose tissue represents an
abundantly available source of human ECM that has the potential to be used as a cell
supportive scaffold for downstream soft tissue engineering and regenerative medicine
applications.256, 257
The successful formulation of human decellularized adipose tissue (hDAT) was first
described by Dr. Lauren Flynn in 2010 using subcutaneous adipose tissue collected from
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surgeries involving breast or abdominal reductions.256 The fabrication process involved an
optimized decellularization protocol that subjected the adipose tissue to sequential physical,
chemical and biological treatment steps, without the use of detergents. Following
decellularization, the majority of the cellular components of native adipose tissue were
removed, leaving a significant amount of ECM with highly conserved protein architecture.256
In-depth macroscopic investigation of the hDAT revealed an intact 3D collagen network
structure with biochemical and biomechanical properties similar to the native tissue.258 When
analyzing the proteomic composition of the hDAT, collagen was found to be the most
abundant protein (~80% of the total protein extract), with collagen 1A1, collagen 1A2 and
collagen 3A1 being the predominant subtypes amongst the 21 collagen proteins detected.255
Other proteins involved in the VEGF, epidermal growth factor (EGF), FGF and SDF-1
signaling pathways were also detected.255 Following seeding with adipose-derived
stem/stromal cells (ASCs) in vitro, it was found that the hDAT scaffolds provided a
supportive microenvironment leading to widespread infiltration and distribution.256 When the
ASC seeded hDAT construct was applied in vivo and subcutaneously implanted into an
immunocompetent rat model, it demonstrated the capacity to stimulate a pro-regenerative
immune and angiogenic response through the recruitment of pro-regenerative M2
macrophages.259
While the hDAT scaffolds have not been previously explored with HPCs, other studies
involving hematopoietic stem cells cultured in porous collagen microbeads showed that the
3D collagen microenvironment was important for expansion and preservation of
hematopoietic stem/progenitor cell phenotype over extended periods of time.260
Alternatively, it may be possible that the hDAT matrix could be influential in guiding
hematopoietic differentiation towards highly regenerative lineages such as monocytes and
macrophages. For example, studies looking at engineered matrices found that fibrillar
constructs with varying stiffness and GAG content were instrumental in guiding monocyte
differentiation and determining macrophage polarity.261 Furthermore, the exact role that
adipose tissue in the bone marrow compartment plays in guiding hematopoiesis is still under
intense investigation.262 In the marrow, adipocytes are believed to be involved in regulating
HSC proliferation and differentiation through the secretion of factors such as adiponectin, IL-
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6 and leptin.263-265 Overall, the hDAT provides a complex ECM microenvironment with a
multitude of structural and bioactive proteins that may directly influence seeded cells.

1.6 Project overview
PAD caused by the accumulation of atherosclerotic plaque in the distal extremities, affects
over 200 million people worldwide, and costs healthcare organizations billions of dollars
annually. Individuals with severe limb ischemia, resting pain and non-healing ulcers are
diagnosed with the most serious form of PAD known as CLI and 30% of patients require
lower limb amputation one year post-diagnosis. Unfortunately, many patients with advanced
CLI are not eligible for any of the gold standard surgical revascularization techniques and
amputation remains the only treatment option. Regenerative medicine based techniques
aimed at stimulating new blood vessel formation using cell and gene therapies have
demonstrated promising results in preclinical animal studies and human clinical trials. While
many of these therapies have shown efficacy in improving blood flow in the affected limb
and reducing pain scores, further refinement is needed to have an impact on patient
amputation rates and mortality.
Hematopoietic progenitor cells are rare cells that can be easily purified from umbilical cord
blood based on the highly conserved stem cell marker, ALDH. When applied to animal
models of CLI, HPC have shown promising pro-angiogenic paracrine function following
intramuscular transplantation, inducing new vessel formation despite limited cell engraftment
at the ischemic site. To improve HPC survival following administration and to prolong proangiogenic paracrine functions, this project applied an interdisciplinary approach using
naturally-derived human decellularized adipose tissue bioscaffolds as a novel, 3D cell culture
and delivery platform. Overall, the primary goal for this study was to characterize the effect
that hDAT had on the survival, proliferation and differentiation of seeded HPC and to
develop an innovative cell therapy harnessing the supportive qualities of hDAT scaffolds and
established pro-angiogenic functions of expanded HPC.

1.7 Hypotheses
The in vitro hypotheses for this project were that ALDHhi HPC would demonstrate
augmented cell viability and proliferation following seeding within hDAT scaffolds
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compared to conventional culture on tissue culture plastic (TCP). Additionally, it was
hypothesized that HPC seeded in hDAT scaffolds would retain their primitive functional and
cell surface phenotype when compared to suspension cultured HPC. For the in vivo objective
of this project, it was hypothesized that ALDHhi HPC seeded in hDAT scaffolds delivered to
the ischemic hindlimb of immunodeficient mice following FAL would result in increased
vessel formation in situ, enhanced recovery of perfusion and improved usage of the ischemic
limb when compared with intramuscularly injected HPC in saline.

1.8 Objectives
The main objectives of this Master’s project were to:
Objective 1: Characterize the interaction of umbilical cord blood derived HPC seeded in
hDAT scaffolds through the direct assessment of cell viability, ALDH activity, proliferation
and cell phenotype in vitro.
Objective 2: Assess the pro-regenerative potential of transplanted UCB-derived HPC seeded
in hDAT scaffolds relative to HPC delivered intramuscularly, unseeded hDAT scaffolds, and
saline alone controls in immunodeficient NOD/SCID mice with FAL-induced CLI.
.
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Chapter 2

2

Materials and methods

2.1 HPC purification and expansion
2.1.1

Purification of ALDHhi cells from umbilical cord blood

Cells were derived from umbilical cord blood (UCB) harvested during scheduled C-sections
at the London Health Sciences Birthing Center in Victoria Hospital. Studies were approved
by the Human Studies Research Ethics Board at Western University (HSREB# 12934, see
Appendix 1). Up to 50 mL of blood was collected per sample through venipuncture of the
umbilical vein (Figure 2.1 A). Blood was processed within 24 hours to ensure the maximum
HPC viability.202
UCB was lineage depleted (Lin-) through the addition of 5 µL of RosetteSep™ human
hematopoietic progenitor cell enrichment cocktail (Stem Cell Technologies, Vancouver, BC)
per milliliter of UCB and incubated for 45 minutes at room temperature. Following the
incubation, UCB was diluted two-fold with sterile phosphate buffered saline (PBS, Gibco,
Invitrogen, Carlsbad, CA) and 10 mL of the diluted UCB was carefully layered on 4 mL of
Ficoll-Paque density gradient medium (GE Healthcare, Marlborough, MA) in 15 mL Falcon
conical tubes (Corning Life Sciences, Corning, NY). Layered UCB was centrifuged at 450 x
g for 20 minutes with the brake set to 0 resulting in the well-defined layer of blood plasma,
mononuclear leukocytes, Ficoll-Paque and unwanted mature hematopoietic cells from top to
bottom (Figure 2.1). The concentrated mononuclear cell suspension (buffy coat) was
carefully aspirated using a Pasteur Pipette (Fisher Scientific, Hampton, NH) and placed in 50
mL conical tubes (Corning Life Sciences, Corning, NY). Collected mononuclear cells were
diluted 2-fold with sterile PBS containing 5% fetal bovine serum (5% FBS/PBS,
ThermoFisher, Waltham, MA) and centrifuged at 450 x g for 7 minutes to remove residual
plasma and Ficoll-Paque. Cells were resuspended in 5% FBS/PBS and 0.8% ammonium
chloride (StemCell Technologies, Vancouver, BC) was added at a 1:9 ratio and incubated at
room temperature for 8 minutes to lyse remaining red blood cells (RBC). Following RBC
lysis, cells were centrifuged at 450 x g for 7 minutes, counted using trypan blue viability dye
and a hemocytometer and resuspended in 1 mL of Aldefluor Assay buffer (StemCell
32

Technologies, Vancouver, BC) for every 107 cells in suspension. Cells were passed through a
40 µm nylon mesh filter (Corning Life Sciences, Corning, NY) into a sterile 15 mL conical
tube to remove cell clusters and 5 µL of AldeflourTM reagent, a fluorescent substrate of
ALDH ( Stem Cell Technologies, Vancouver, BC), was added per mL of Aldefluor assay
buffer. Cells were incubated for 30 minutes at 37 °C to facilitate the intracellular
accumulation of the fluorescent biproduct of Aldefluor in cells with high ALDH-activity.
Purification of progenitor cells on the basis of high ALDH activity was completed by Dr.
Kristin Chadwick using fluorescence activated cell sorting (FACS) on the BD FACSAria™
III (BD Biosciences, San Jose, CA) in the London Regional Flow Cytometry Facility
(LRFCF), Robarts Research Institute. Regions for the selection of cells with high versus low
ALDH-activity were determined based on the fluorescent intensity of cells that received
AldeflourTM reagent and were immediately transferred to a 15 mL conical tube containing 5
µL of the ALDH-inhibitor, DEAB (StemCell Technologies, Vancouver, BC).

33

Figure 2.1 Objective 1 methodology and timeline for the in vitro characterization of UCBderived HPC seeded into hDAT scaffolds. (A) Purification and expansion protocol for UCB
derived ALDHhi HPC. (B) Timeline for in vitro analysis of cell viability, proliferation, cell
surface phenotype and ALDH activity for cells extracted from hDAT scaffolds, collected from
the scaffold supernatant or cultured on TCP. (C) Representative images for all end point in
vitro assays including cell viability, proliferation, ALDH activity and cell phenotype using
flow cytometry.
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2.1.2

Expansion of ALDHhi HPC

For cell expansion prior to subsequent experiments, 1 x 105 sorted cells with high ALDHactivity (ALDHhi) were plated on fibronectin-coated (Sigma-Aldrich, St. Louis, MO) T-25
tissue culture plastic (TCP) flasks (Corning Life Sciences, Corning, NY) and expanded using
optimized, serum-free and hematopoietic lineage-specific culture media X-Vivo 15 (Lonza,
Basel, Switzerland) supplemented with 10 ng/mL of stem cell factor (SCF), Fms-related
tyrosine kinase 3 ligand (Flt3L), and thrombopoietin (TPO, all from Life Technologies,
Carlsbad, CA). Media was changed every 3 days. Cells were expanded for 6 days to obtain
adequate HPC number for experiments without the loss of vascular regenerative function.164

2.2 hDAT scaffold production
2.2.1

Adipose tissue decellularization protocol

Chemicals and reagents involved in hDAT scaffold production were purchased from SigmaAldrich (St. Louis, MO), unless otherwise stated. hDAT scaffolds were synthesized from
subcutaneous fat tissue harvested from patients receiving elective surgery for abdomen or
breast reduction at London Health Sciences Centers (Cumberland Clinic, St. Joseph’s
Hospital or University Hospital, London, ON). Human Research Ethics Board approval was
obtained from Western University (HREB# 105426, see Appendix 3). Patient information
including age, sex, height, weight and excision site was collected and recorded. All hDAT
used during this project was derived from adipose tissue pooled from 5 donors.
The decellularization protocol used throughout this project was an established, 5-day
detergent-free process involving mechanical disruption, polar solvent extraction to remove
lipid content, and enzymatic digestion to remove cells and cellular components, as previously
documented in Flynn 2010.256 First, adipose tissue was transported to the lab on ice in sterile
PBS containing 20 mg/mL bovine serum albumin (BSA). The tissue was carefully examined
and portions of cauterized tissue and large blood vessels were removed and discarded. The
tissue was then cut into 3 cm3 blocks to increase the surface area and placed into 100 mL of
hypotonic buffer solution (pH 8.0) containing 10 mM Tris base, 5 mM
ethylenediaminetetraacetic acid (EDTA), 1% (v/v) antibiotic-antimycotic solution (ABAM,
Gibco, Invitrogen, Carlsbad, CA) and 0.27 mM of the protease inhibitor
phenylmethanesulphonylfluoride (PMSF).
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The tissue tubs were placed in a -80°C freezer. Following liquid and tissue freezing, the tubs
were removed and placed in a 37°C agitating incubator set to 120 rpm until completely
thawed. The liquid was removed and replaced with new freezing buffer solution, including
fresh ABAM and PMSF. This freeze/thaw cycle was repeated twice more, until a total of 3
freeze/thaw cycles had been completed. Following the final thaw cycle, the freezing solution
was replaced with 50 mL of an enzymatic digestion solution comprised of 0.25% Trypsin/
0.1% EDTA solution (Gibco, Invitrogen, Carlsbad, CA), 1% (v/v) ABAM and placed in the
agitating incubator overnight. The next morning on day 2, the enzymatic digestion solution
was removed and replaced with 100 mL of polar solvent solution containing 99.9%
isopropanol, 1% (v/v) ABAM and 0.27 mM PMSF. The tissue was gently massaged and left
in the 37°C agitating incubator for 8 hours. Polar solvent solution replacement and tissue
massaging was repeated and the tubs were placed back into the 37°C agitating incubator
overnight. This polar solvent solution and tissue massage process was repeated again on day
3 and the tubs were returned to the 37°C agitating incubator overnight. On the morning of
day 4, the tissue was rinsed three times in a solution containing 100 mL of Sorensen’s
phosphate buffer (SPB) solution (pH 7.3, 147 g/L Na2HPO4•7H2O and 23 g/L KH2PO4), 1
mL ABAM and 7 µL PMSF. The tissue was agitated in a 37°C incubator for 30 minutes and
the rinsing solution was discarded between rinses. Following rinses, the tissue was placed in
enzymatic digestion solution containing 50 mL 0.25% Trypsin/ 0.1% EDTA and 1% (v/v)
ABAM and left in an agitating incubator at 37°C for 6 hours. The tissue was then rinsed 3
times using the SPB rinsing solution and incubated overnight in 200 mL of SPB digest (pH
7.3 147 g/L Na2HPO4•7H2O, 23 g/L KH2PO4 and 12g/L MgSO4•7H2O) containing 13,000
units of type I DNase from bovine pancreas, 12.5 mg of type IIIA RNase from bovine
pancreas, 2000 units type IV-S lipase from porcine pancreas, 2 mL ABAM and 0.27 mM
PMSF. On the morning of day 5, the enzymatic digestion solution was replaced with 100 mL
of polar solvent extraction solution containing 99.9% isopropanol, 1% (v/v) ABAM and 0.27
mM PMSF and placed in an agitating 37°C incubator for 8 hours. The tissue was rinsed three
times with SPB rinsing solution followed by 3 decontamination rinses in 70% ethanol before
being stored at 4°C in PBS containing 1% ABAM until future use.
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2.3 Preparation of hDAT suspension and scaffold fabrication
To produce a uniform ECM suspension for successful hDAT porous foam scaffold
fabrication, the Nishihara collagen solubilization methods described by F. S. Stevens were
adapted for use with hDAT as follows (Figure 2.2).266 Stored hDAT was removed from the
PBS solution, excess fluid was removed, and the samples were washed with PBS three times
for 30 minutes under agitation at room temperature. Following the last wash step, the tissue
was placed in a -20°C freezer overnight before being lyophilized for 48 hours. Following
lyophilisation, the freeze-dried tissue was minced into 0.5 mm fragments and 75 mg was
placed in a cryomilling chamber with two large stainless-steel milling balls. This chamber
was submerged in liquid nitrogen for 3 minutes and subsequently milled on a Retsch Mixer
Mill 400 (Retsch, Haan, Germany) for 3 minutes at 1800 rpm. The chamber was placed back
into liquid nitrogen for 3 minutes and the milling/freezing procedure was repeated twice
more for a total of 3 milling cycles.
The finely cryomilled hDAT tissue was collected from the chambers using a round-edge
scoopula and 1 g (dry weight) of the decellularized adipose tissue powder was digested in
10 mL of 0.22 mM NaH2PO4 solution (pH 5.4) containing 10 mg of a-amylase (1% w/w of
dry tissue). The liquid volume was recorded, and the samples were digested for 72 hours
under constant agitation at room temperature. Following digestion, the samples were
centrifuged at 1500 x g for 10 minutes and the supernatant was removed and discarded. Next,
10 mL of 5% (w/v) NaCl solution was added to the digested tissue and the mixture was left
to agitate for 10 minutes. The tissue was centrifuged again at 1500 x g for 10 minutes and
was rinsed once more with 5% NaCl solution for a total of two rinses. Following the second
rinse, the supernatant was removed and replaced with 10 mL of double-distilled water
(ddH2O) and left to agitate for 10 minutes at room temperature. Following rinse steps with
NaCl and ddH2O, the tissue suspension was centrifuged at 1500 x g for 7 minutes and the
supernatant was replaced with 0.2 M acetic acid up to the volume recorded previously. The
samples were lightly vortexed and placed on a temperature regulated incubator shaker set to
120 rpm and 37°C overnight.
The next day, the samples were homogenized with a Fisher Scientific Power Gen 125 hand
held homogenizer (Fisher Scientific, Hampton, NH) using 5 second pulses at a setting of 6.
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The solution was cooled on ice between three homogenization bursts to prevent the sample
from over-heating. The homogenous hDAT suspension was diluted to 25 mg/mL (based on
starting tissue mass) with 0.2 M acetic acid and 250 µL of the suspension was pipetted into
each well of a 48 well plate, frozen in a -80°C freezer and lyophilized to form the final
cylindrical-shaped porous foam with a diameter of 1 cm and height of 0.2 mm. The scaffolds
were stored in 100% ethanol at 4°C until they were needed and were rehydrated through
sequential 30 minute rinses in 100:0, 70:30, 0:100 solutions of ethanol:PBS, followed by a 60
minute incubation in 10 mL of X-Vivo 15 supplemented with 10 ng/mL of SCF, TPO and
Flt3L prior to cell seeding.
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Figure 2.2 Macroscopic overview for adipose tissue decellularization and scaffold
fabrication. (A) Freshly excised adipose tissue prior to decellularization. (B) Tissue following
polar solvent extraction and massaging. (C) hDAT following complete decellularization
process and rehydration with PBS. (D) hDAT following 48 hour lyophilization. (E) Finely
minced pieces of lyophilized hDAT (F) Cryomilled hDAT prior to hDAT suspension
(G) hDAT scaffold fabrication through lyophilization in 48-well plate (H) Final hDAT
scaffold with a diameter of 1 cm and height of 0.2 cm. Scale bar represents 1 cm. Image
adapted from Morissette Martin et al.2
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2.4 HPC seeding and extraction from hDAT scaffolds
2.4.1

HPC seeding into hDAT scaffolds

All experiments in this project utilized the same methodologies for the effective seeding of
HPC into hDAT scaffolds. Following 6 days of expansion, non-adherent cells were collected
and placed in a 15 mL Falcon tube. Next, 1 mL of trypsin (TrypLE Express, Gibco,
Invitrogen, Carlsbad, CA) was added to each T-25 flask and the flasks were incubated for 10
minutes at 37°C to detach any remaining adherent cells. Lifted adherent cells were collected
and added to the non-adherent fraction. Cells were centrifuged at 450 x g for 7 minutes and
resuspended in 1 mL of supplemented X-Vivo 15 for cell counting using the Countess II
automated cell counter (ThermoFisher Scientific, Waltham, MA). HPC were statically
seeded into rehydrated hDAT foams at 5 x 105 cells/scaffold in a 48-well plate containing
600 µL of supplemented X-Vivo 15 per well and cultured for up to seven days in vitro. HPC
cultured without hDAT scaffolds were included alongside hDAT groups as TCP controls.

2.4.2

Cell extraction from hDAT scaffolds

For the in vitro characterization of the HPC phenotype after seeding into the hDAT scaffolds,
flow cytometric analysis required the analyses of cells extracted from hDAT that contained
fragments of contaminating scaffold debris. Excess scaffold debris that could not be removed
through filtration resulted in difficulty discriminating between autofluorescent ECM
particulates and isolated cells. Variable amounts of scaffold contamination would frequently
lead to over- or under-representations of marker frequencies during analysis. To account for
this, cell-specific stains were included in the viability, proliferation and monocyte /
macrophage phenotype panels to positively select cells for accurate phenotype analysis.
However, the ALDH and primitive cell surface marker expression panel utilized directly
conjugated antibodies with fluorophores incompatible with fluorescent cellular dyes and
required a centrifugation step on Ficoll-Paque to remove debris using a density gradient,
described below.
The TCP and supernatant samples were collected using a pipette and remaining adherent
cells were detached using previously mentioned methods involving a short incubation with
TrypLE expressTM. ALDH and cell surface phenotype expression was analyzed at the time of
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seeding (day 0) and all in vitro assay analyses were performed at days 1, 3 or 7 post-seeding
to monitor the effects of the hDAT on the HPC phenotype over time.

2.4.2.1

Cell processing for viability, proliferation and cell surface
marker expression analyses

hDAT scaffolds were removed from wells using flat forceps and placed in a 5 mL round
bottom plastic tube (Corning Life Sciences, Corning, NY) containing 1 mL of TrypLE
ExpressTM. Cells in the scaffolds were enzymatically liberated through incubation for 15
minutes within a water bath at 37°C. The resulting cell-ECM suspension was briefly vortexed
to promote detachment of cells from the scaffold. Next, the entire suspension was filtered
through a 50 µm nylon mesh filter (Sysmex, Kobe, Japan) to remove large fragments of
scaffold ECM and rinsed twice to wash out trapped cells remaining on the filter. To
characterize cells that did not attach directly on the scaffold, the supernatant media remaining
in the well following scaffold removal was collected and analyzed.

2.4.2.2

Cell processing for ALDH-activity and primitive cell surface
marker expression analyses

To assess ADLH-activity alongside primitive cell surface marker expression, a density
gradient centrifugation processing step was used to separate cells from scaffold debris.
Following 1, 3 and 7 days of culture, cells were liberated from the scaffolds following the
same TrypLE expressTM digestion for 15-minute at 37°C. Next the cell-ECM suspension was
carefully layered on top of 1 mL of Ficoll-Paque density gradient medium (GE Life Sciences,
Marlborough, MA) and centrifuged at 450 x g for 20 minutes with the brake set to 0. Cells
were collected using a Pasteur pipette at the boundary between the Ficoll-Paque and Trypsin
layers, being careful not to disturb the ECM pellet at the bottom of the tube. Collected cells
were filtered through a 50 µm nylon mesh filter to remove any large ECM fragments not
filtered by the density gradient centrifugation. Cells were then centrifuged and resuspended
in 1 mL of PBS supplemented with 5% FBS and divided among experimental tubes.
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2.5 Cell viability, proliferation, ALDH-activity and phenotype
analyses in vitro
To determine if hDAT scaffolds would be an effective cell delivery vehicle, HPC viability,
proliferation and phenotype were assessed at 1, 3 and 7 days post-seeding and compared to
TCP controls using flow cytometry (BD™ LSR II (BD Biosciences, San Jose, CA) at the
LRFCF. Additionally, ALDH-activity and cell surface marker expression was analyzed
following the 6 day expansion protocol to determine the cell phenotype prior to seeding into
hDAT (Day 0). All flow cytometric analyses were performed in a non-blinded manner.
Samples were resuspended in 300 µL of PBS prior to the addition of the relevant cell stains
or conjugated antibodies to ensure equal distribution of the staining agent. All flow
cytometry data analysis was collected using the BD FACSDiva™ (BD Biosciences, San
Jose, CA) software during cytometer operation and analyzed using FlowJo software (FlowJo
LLC., Ashland, OR).

2.5.1

Cell viability

Cell survival was assessed using Calcein AM (Sigma Aldrich, St. Louis, MO) as a marker for
cell viability, DRAQ5 (ThermoFisher Scientific, Waltham, MA) as a marker for nucleated
cells and Sytox orange (Invitrogen, Carlsbad, CA) as a marker for non-viable cells. DRAQ5
was used in these experiments to distinguish viable and non-viable cells from scaffold debris
and platelets lacking cell nuclei. Cells liberated from the scaffold or unattached cells
remaining in the supernatant, as well as TCP culture controls, were stained sequentially with
Sytox Orange, Calcein AM and DRAQ5 for 15 minutes at 37°C and then analyzed by flow
cytometry. Gates were established for Calcein AM and Sytox orange staining based on
relevant fluorescence minus one (FMO) samples on each day of flow cytometry.

2.5.2

Cell proliferation

To quantify cell proliferation, 10 µM of 5-ethynyl-2-deoxyuridine (EdU, Invitrogen,
Carlsbad, CA) was administered to each well 24 hours prior to analysis. HPC extracted from
hDAT scaffolds, or collected from the supernatant, or cultured on TCP were fixed in a 10%
formalin solution (Fisher Scientific, Hampton, NH) for 10 minutes, permeabilized in saponin
buffer solution (Invitrogen, Carlsbad, CA) for 15 minutes and cell proliferation was assessed
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using the Click-iT™ EdU Alexa Fluor™ 488 Imaging Kit (Invitrogen, Carlsbad, CA). Gates
were established for EdU positive cells based on FMOs for cells cultured without EdU.

2.5.3

ALDH Activity and Primitive Cell Surface Marker Expression

Cell surface marker expression was characterized through conjugated antibody staining with
1:150 BV421 CD34 (BD Biosciences, San Jose, CA), 1:150 APC CD133 (BioLegend, San
Diego, CA) and 1:100 of PE CD38 (BD Biosciences, San Jose, CA) per tube, and incubated
for 45 minutes at 4°C. Cells were then rinsed with 3 mL PBS and centrifuged at 450 x g for 7
minutes to remove residual antibodies. Next, cells were resuspended in 300 µL of Aldefluor
assay buffer (StemCell Technologies, Vancouver, BC) and 1 µL of Aldefluor was added to
each tube prior to a 30-minute incubation at 37°C. Samples were centrifuged for 7 minutes at
450 x g and resuspended in 300 µL fresh Aldefluor assay buffer to wash out residual
Aldefluor reagent. To identify cells with high ALDH-activity, gates were established using
DEAB treatment at the time of Aldefluor staining. Positive expression of each cell surface
marker was identified through use of relevant FMOs at each timepoint.

2.5.4

Monocyte and macrophage marker expression

To evaluate whether hDAT scaffolds promoted the differentiation of seeded HPC, cell
surface markers enriched on monocyte, macrophage and megakaryocyte lineages were
analyzed. Following cell extraction from the hDAT scaffolds or TCP, samples were pelleted
at 450 x g for 7 minutes and resuspended in 300 µL of 5% FBS/PBS. Next, CellTracker™
Green CMFDA Dye (Invitrogen, Carlsbad, CA) was prepared according to the
manufacturer’s instructions and 100 µL of the 10 µM solution was added to each sample and
all tubes were placed in a 37 °C incubator for 30 minutes to mark viable cells. Following
incubation, samples were washed with 3 mL of 5% FBS/PBS, centrifuged at 450 x g for 7
minutes and resuspended in 10% formalin solution for 5 minutes at room temperature. The
cells were washed again with 3 mL of 5% FBS/PBS and centrifuged at 300 x g for 7 minutes
before being permeabilized in saponin buffer solution for 20 minutes.
Samples were distributed for single-stain analysis for CD14 (monocyte), CD11b
(macrophage) and CD42b (megakaryocyte/platelet), and multi-stain analysis for CD68
(macrophage), and CD163 (M2 macrophage). Each single stain tube received 1:150 of
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APC/Cy7 CD14 (Biolegend, San Diego, CA), 1:150 µL of PE CD11b (Biolegend, San
Diego, CA) or 1:150 µL of PE CD42b (Biolegend, San Diego, CA). Multi-stain tubes
received 1:150 µL of PE CD68 (Biolegend, San Diego, CA) and 1:150 of APC CD163
(Biolegend, San Diego, CA).

Table 2.1 Antibody specifications for flow cytometry protocols
Antibody

Fluorophore

Clone

Catalog #

Company

Monoclonal
mouse antihuman CD34

BV421

Clone 581

562577

BD Biosciences,
San Jose, CA

Monoclonal
mouse antihuman CD133

APC

Clone 7

372806

Biolegend, San
Diego, CA

Monoclonal
mouse antihuman CD38

PE

HIT2

555460

BD Biosciences,
San Jose, CA

Monoclonal
mouse antihuman CD14

APC/Cy7

M5E2

301820

Biolegend, San
Diego, CA

Monoclonal
mouse antihuman CD11b

PE

ICRF44

301306

Biolegend, San
Diego, CA

Monoclonal
mouse antihuman CD42b

PE

HIP1

303906

Biolegend, San
Diego, CA

Monoclonal
mouse antihuman CD68

PE

Y1/82a

333808

Biolegend, San
Diego, CA

Monoclonal
mouse antihuman CD163

APC

GHI/61

333610

Biolegend, San
Diego, CA
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2.6 Femoral Artery Ligation and Transplantation of HPC
seeded hDAT Scaffolds
2.6.1

Animals

All animal procedures used were performed in accordance with the rules and regulations set
by the Canadian Council on Animal Care (CCAC) and were outlined in the animal use
protocol #2015-012 (Appendix 2) approved by the Animal Care Committee at Western
University. All in vivo experiments were performed on 8- to 10-week old NOD.CB17Prkdcscid/J mice (NOD/SCID mice) ordered from Jackson Laboratories (Stock number
001303, Jackson Laboratories, Bar Harbor, ME). NOD/SCID mice were selected for the
transfer of HPC-seeded hDAT scaffolds based on their complete lack of mature T- and Bcells and reduced NK cell function.267 These reductions in adaptive and innate immunity
permit human cell engraftment without xeno-rejection. For mice euthanized at day 14 postsurgery, mice were intraperitoneal (IP) injected with 200 µg of EdU (Invitrogen, Carlsbad,
CA) 24 hours prior to sacrifice for the labelling of proliferating cells in situ. Male and female
NOD/SCID mice were divided among treatment groups at random. All in vivo analysis was
collected in a non-blinded manner.

2.6.2

Femoral Artery Ligation Surgery

To evaluate the efficacy of hDAT scaffolds as a cell supportive delivery vehicle for expanded
HPC compared to IM injection, day 6 expanded HPC were seeded into hDAT scaffolds (5 x
105 cells) 24 hours prior to FAL surgery and implanted into the ischemic limb of
immunodeficient NOD/SCID mice at the site of femoral artery ligation and excision in the
right hindlimb (Figure 2.2A). Unseeded hDAT scaffolds were similarly implanted to serve as
cell-free controls. Intramuscular (IM) saline injection, and mice IM-injected with HPC in
solution were used as a hDAT scaffold-free controls. Cell doses were selected based on
previously published experiments completed by the Hess lab.164, 165 In total, four treatment
groups were studied: day 6 expanded HPC in hDAT scaffold, day 6 expanded HPC IM
injected, scaffold only and saline vehicle controls. A total of 9 mice were included for each
group. Each mouse within the HPC-seeded hDAT and IM injected HPC treatment groups
received cells from a unique biological UCB sample.
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To induce unilateral hind limb ischemia in the mice, femoral artery and vein ligation
followed by excision (2 – 5 mm portion) was completed following an established
protocol.268 Briefly, mice were anesthetized by an IP injection of 100 mg/kg ketamine and 10
mg/kg xylazine, and maintained using 2% isoflurane (Baxter Corperation, Deerfield, IL).
Prior to surgery, the medial side of both limbs were shaved using a sterilized electric shaver.
Following shaving, Nair (Church & Dwight, Ewing, NJ) was applied generously from the
feet to the hips to remove remaining hair. After 10 minutes, the Nair was removed using a
sterile gauze pad and the region was sequentially washed using soapy water, 70% ethanol
and chlorhexidine gluconate. Next, each mouse was positioned under a dissection
microscope with their limbs taped down to the surface. Using forceps, the skin proximal to
the knee joint was pinched and a scalpel was used to make an incision (2 – 3 mm) directly
above the underlying femoral artery. Subcutaneous fat was carefully removed using forceps
and tissue cauterizer. To expose the neurovascular bundle, the membranous fascia
surrounding the adductor muscle was carefully removed using fine pointed forceps. The
parallel femoral nerve was separated from the vessels using a blunt probe. Using 7-0 silk
sutures, the femoral artery and vein were ligated at the proximal femoral artery (immediately
distal to the bifurcation of the internal iliac artery) and distal femoral artery (proximal to the
bifurcation into the saphenous and popliteal arteries). Sutures were positioned 3 – 5 mm apart
with the superficial epigastric artery bifurcation present between them. The femoral artery
and vein were carefully excised using a tissue cauterizer at sites distal to the proximal suture
and proximal to the distal suture. Prior to incision closure, hDAT scaffolds with or without 5
x 105 expanded HPC were transplanted over the ligation site, or 100 µL saline with or
without 5 x 105 cultured HPC was directly injected into 2 sites on the thigh and
gastrocnemius muscle.
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Figure 2.3 Objective 2 methodology and timeline for the in vivo application of HPC
delivered in hDAT scaffolds in a immunodeficient mouse model of CLI. (A) To induce
hindlimb ischemia, NOD/SCID mice underwent unilateral femoral artery and vein ligation and
excision and were treated with HPC-seeded hDAT scaffolds, IM injection of HPC in saline,
scaffold only, or IM injection of saline. (B) Ischemic and non-ischemic thigh muscle sections
were examined for CD31 vessel density and CD45 human cell engraftment. CatWalkTM gait
analysis was used to quantify functional limb recovery through analysis of ischemic paw print
area and intensity relative to non-ischemic limb values. RH: Right Hind Limb, LH: Left Hind
Limb, RF: Right Front Limb, LH: Left Hind Limb
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2.6.3

Laser Doppler Perfusion Imaging and CatWalk Gait Analysis

To assess the recovery of limb perfusion, laser Doppler perfusion imaging (LDPI) was
performed weekly for up to 35 days (Figure 2.1 A). Perfusion ratios (PR) were generated the
day after surgery to ensure successful reduction in limb perfusion (PR of < 0.15 for
ischemic/non-ischemic limbs). For limb perfusion analysis, the region of interest included the
dorsal portion of the hind paw that was distal to the ankle joint. For LDPI measurements at
days 1, 7, 14, 21, 28 and 35 post-surgery, mice were anesthetically induced using 4%
isoflurane/oxygen and maintained at 2% isoflurane/oxygen for the duration of the assay (10
minutes). Mice were warmed for 5 minutes at 37°C prior to measuring hind limb perfusion
using the Moor Instruments laser Doppler perfusion imager (Moor Instruments, Devon, UK).
Ischemic limb perfusion was quantified using the Moor Instruments software and flux
intensity within the ischemic limb was divided by the non-ischemic limb to calculate the PR.
To assess the recovery of limb usage, CatWalkTM gait analysis (Noldus, Wageningen,
Netherlands) was performed at days 7 and 14 in Robarts Research Institute’s integrative
neurobehavioral facility using the CatWalk equipment and software (CatWalk 7.1, Noldus,
Wageningen, Netherlands). Four complete runs with minimal pivoting and involving >4
footprints per limb were collected for each mouse. Each run was analyzed individually and
functional recovery was quantified based on the ratio of print intensity and print area for the
ischemic versus non-ischemic hindlimbs.

2.6.4

Histological evaluation of revascularization

Hindlimb adductor and gastrocnemius muscles from the ischemic and control limbs were
collected at day 14 or at day 35 and frozen in optimal cutting temperature medium (OCT,
Fisher Scientific, Hampton, NH). Adductor muscle blocks were cryosectioned at a thickness
of 15 µm and stored in a -80°C freezer until needed. To prepare the frozen sections for both
immunofluorescent and colourmetric staining, tissue sections were fixed using a 10%
formalin solution for 15 minutes before being rinsed twice with PBS for 10 minutes. To
permeabilize the tissues, sections were incubated in 1% Triton-X detergent (Sigma-Aldrich,
St. Louis, MO) for 20 minutes. All antibody staining was performed at room temperature.
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2.6.4.1

Immunofluorescent staining for day 14 adductor muscles

Permeabilized tissue sections from day 14 adductor muscles were subjected to two 10
minutes rinses using PBS, and the sections were evaluated for human cell engraftment. First,
all sections were incubated in 100 µL of 5% goat serum blocking agent (Vector Labs,
Burlingame, CA) for 1 hour to reduce non-specific binding. Next, sections were covered with
rabbit anti-human CD45 antibody (Abcam, Cambridge, UK) diluted in 5% goat serum at
1:100 for 1 hour. Following two 10 minute washes with PBS, sections were covered with 5%
goat serum solution containing 1:100 alexafluor 647 goat anti-rabbit secondary (Jackson
ImmunoResearch Laboratories, Inc., Westgrove, PA) for 30 minutes. Finally, the sections
were rinsed twice with PBS and cell nuclei were stained using 4',6-Diamidino-2Phenylindole, Dihydrochloride (DAPI, Invitrogen, Carlsbad, CA) according to the
manufacturer’s specifications. Each slide was thoroughly rinsed in double-distilled water
(ddH2O) and mounted in Vectamount aqueous mounting medium (Vector Labs, Burlingame,
CA). Two complete sections from the surgical and non-surgical limb were analyzed for each
animal and imaged using the Leica Aperio Versa 8 (Leica, Wetzlar, Germany) and human
CD45+ cell engraftment was quantified using ImageJ (ImageJ software, National Institute of
Health, Bethesda, MD).

2.6.4.2

Colourmetric CD31 capillary density quantification

Following tissue permeabilization and two rinses in PBS for 10 minutes, all sections were
incubated in 100 µL of 5% goat serum blocking agent for 1 hour. Rat anti-mouse CD31 (BD
Biosciences, San Jose, CA) diluted 1:100 in 5% goat serum was added to cover each tissue
section and incubated for 45 minutes. Following primary antibody incubation, tissue sections
were rinsed twice with PBS for 10 minutes and incubated in 50 µL of 1:100 peroxidaselabelled anti-rat secondary (Vector Labs, Burlingame, CA) for 30 minutes. Peroxidaselabelled CD31 regions were chromogenically detected using 3,3'-diaminobenzidine (DAB,
Vector Labs, Burlingame, CA), a chemical substrate that turns brown in regions with
horseradish peroxidase activity. Sections were mounted using Vectamount aqueous mounting
solution and 14 images at 3 tissue depths for each limb were acquired in a blinded fashion on
the Olympus BX50 (Olympus, Tokyo, Japan). CD31+ cell area was quantified for each image
and ischemic to non-ischemic CD31 positive ratios were calculated for each mouse using
ImageJ.
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Table 2.2 Specifications for immunohistochemistry protocols

Blocking Agent
Primary Antibody

Secondary Antibody
a

CD45

CD31

PBS + 5% Goat serum

PBS + 5% Goat serum

Rabbit anti-human monoclonal

Rat anti-mouse monoclonal

CD45 (Cat. Ab 40763)a

CD31 (Cat. 550274)b

Goat anti-rabbit, Alexafluor 647

Goat anti-rat, peroxidase

(Cat. 111-605-003)c

labelled (Cat. Pl-9400)d

Abcam, Cambridge, UK bBD Biosciences, San Jose, CA cJackson Immunoresearch,

Westgrove, PA dVector Laboratories, Burlingame, CA

2.7 Statistics
For cell viability, cell proliferation, ALDH assays and cell surface marker expression
analyses in vitro, a two-way analysis of variance (ANOVA) was performed followed by a
Tukey’s post hoc multiple comparisons test. For LDPI and CatWalk gait analyses, a two-way
repeated measures ANOVA was completed followed by a Tukey’s post hoc multiple
comparisons test. Assessment of revascularization using CD31 DAB staining was analyzed
using a one-way ANOVA followed by a Tukey’s post hoc multiple comparisons test. All
statistical analyses were completed using the GraphPad Prism 7 software. Outliers were
detected using a Grubb’s test with a p < 0.05.
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Chapter 3

3

Results

3.1 HPC within hDAT scaffolds demonstrated increased
viability in vitro
Previous experiments performed by the Hess laboratory have extensively characterized the
regenerative capacity of fresh umbilical cord blood (UCB) ALDHhi hematopoietic progenitor
cells (HPC) or day 6 expanded ALDHhi HPC when intramuscularly (IM) injected into the
femoral artery ligation (FAL) mouse model of critical limb ischemia (CLI).164, 165
Unfortunately, due to severe ischemia in the surgical limb and poor survival in muscle tissue,
cell engraftment was rarely detected at day 7 near the site of injection.163 The central
objective of this study was to augment cell retention near the surgical site using a cellsupportive matrix derived from human decellularized adipose tissue (hDAT).
To evaluate the viability of day-6 expanded HPC seeded in hDAT scaffolds in vitro, calcein
AM and sytox orange was used to label viable and non-viable cells, respectively, and live /
dead cells were quantified by flow cytometry over 7 days in culture. HPC seeded in hDAT
scaffolds demonstrated significantly higher frequencies of viable (Calcein+ / Sytox-) cells at
day 3 (84.1 ± 3.6 %, *p < 0.05) and day 7 (86.4 ± 3.4 %, *p < 0.05) compared to the cells in
the supernatant collected from above the hDAT scaffolds (70.0 ± 6.3 % at D3 and 69.6 ± 3.4
% at D7, Figure 3.1 A,B) and HPC cultured on TCP (70.2 ± 6.7 % at D3 and 70.7 ± 4.1 % at
D7). Notably, while viable cell frequency decreased from day 1 through 7 for cells cultured
on TCP (87.6 ± 1.5 % to 70.7 ± 4.1, *p < 0.05) and remaining in the supernatant (87.4 ± 1.8
% to 69.6 ± 3.4 %, **p < 0.01), cell viability was not significantly different between
timepoints for the cells extracted from within the hDAT scaffolds.
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Figure 3.1 Culture in hDAT scaffolds increased HPC viability in vitro.
(A) Representative flow cytometry plots showing Calcein AM (viable) and Sytox orange
(non-viable) fluorescence of cells extracted from the hDAT scaffolds, collected from the
scaffold supernatant, or cultured on TCP at 7 days post-seeding. (B) High HPC viability
was maintained for 7 days in hDAT scaffolds and the frequency of viable cells was increased
at day 3 and 7 compared to cells cultured on TCP or cells collected from the scaffold
supernatant. Data is shown as mean ± SEM (N = 7 UCB samples) and evaluated for
statistical differences using a two-way ANOVA followed by Tukey’s post-hoc multiple
comparisons test (*p < 0.05).
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3.2 HPC within hDAT scaffolds demonstrated increased
proliferation in vitro
Next, to assess the proliferative capacity of HPC within the hDAT scaffolds, EdU
incorporation was used to label cells that had actively divided within 24 hours prior to each
timepoint. The frequency of proliferating cells at days 1, 3 and 7 was determined using flow
cytometry for cells extracted from the hDAT scaffolds, remaining in the scaffold supernatant,
or cultured on TCP. The frequency of proliferating cells was higher at day 7 for cells
extracted from the hDAT scaffolds (52.8 ± 1.6 %) as compared to HPC cultured on TCP
(20.3 ± 5.4 %, *p < 0.05, Figure 3.2 A,B). Cell proliferation was equivalent when comparing
the HPC extracted from the hDAT scaffolds to those collected from the scaffold supernatant,
suggesting that the presence of the scaffolds contributed to proliferation for both populations.
When evaluating differences in HPC proliferation over time, both TCP and supernatant HPC
experienced sequential decreases in the frequency of proliferating cells at day 1 (73.9 ± 4.0 %
and 62.6 ± 8.9 %) compared to day 3 (33.8 ± 9.43 % and 43.1 ± 8.6 %) and day 7 (20.3 ± 5.4
% and 43.0 ± 10.3 %), respectively (Figure 3.2 C). Interestingly, cells extracted from the
hDAT scaffolds demonstrated no significant decrease in the frequency of cell proliferation
over the 7-day time course, indicating HPC expansion was maintained for 7 days in vitro.
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Figure 3.2 Culture in hDAT scaffolds maintained HPC proliferation in vitro. (A)
Representative flow cytometry plots demonstrating the frequency of EdU-labelled cells
extracted from hDAT scaffolds, remaining in the scaffold supernatant, or cultured on TCP
at day 7 post-seeding. (B) The frequency of proliferating cells was increased at day 7 for
cells cultured in hDAT scaffolds compared to cells cultured on TCP (*p < 0.05). Although
HPC cultured on TCP (***p < 0.001) and HPC collected from the scaffold supernatant
(*p < 0.05) showed decreased proliferation frequencies at day 3 and 7 compared to day 1,
HPC cultured in hDAT showed no significant changes in the frequency of proliferating cells
between the time points studied. Data is shown as mean ± SEM (N = 5 UCB samples) and
evaluated for statistical significance using a two-way ANOVA followed by Tukey’s posthoc multiple comparisons test.
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3.3 Culture in hDAT scaffolds did not affect primitive cell
surface marker frequency
In order to evaluate changes in the primitive HPC phenotype after culture in hDAT scaffolds,
multi-parametric flow cytometry was performed on HPC to detect several primitive cell
surface markers (CD34, CD133, CD38) at the time of seeding and after 1, 3 and 7 days of
culture. At the time of HPC seeding, the frequency of day-6 expanded HPC demonstrating
primitive cell surface phenotypes (CD34+CD38- 12.7 ± 1.7 %, CD34+CD133+ 10.9 ± 1.6 %)
were similar to previously-documented values collected by the Hess Lab.164, 206 Cells
extracted from the hDAT scaffolds, remaining in the scaffold supernatant, or cultured on
TCP demonstrated an equivalent frequency of CD34+CD38- cells over the 7-day time course
(Figure 3.3 A,C). Similar to CD34+CD38- HPC frequencies, no significant differences were
observed in the frequency of CD34+CD133+ cells between treatment groups at each
timepoint, but the majority of values remained below frequencies reported at day 0 (Figure
3.3 B,D). Collectively, these data suggest primitive HPC phenotype was not affected by in
vitro culture in the hDAT scaffolds compared to conventional TCP culture methodology.
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Figure 3.3 Cells cultured in hDAT scaffolds and on TCP showed similar frequencies of
primitive phenotype. (A) Representative flow cytometry plots demonstrating the frequency
of CD34+CD38- HPC at day 0 and after 7 days of culture for cells extracted from the hDAT
scaffolds, remaining in the scaffold supernatant, or on TCP. (B) Representative flow cytometry
plots demonstrating the frequency of CD34+CD133+ HPC day 0 and after 7 days culture for
cells extracted from the hDAT scaffolds, collected from the scaffold supernatant, or on TCP.
(C) The frequency of CD34+CD38- cells was equivalent between all treatment groups at each
timepoint. (D) The frequency of CD34+CD133+ HPC was equivalent between all treatment
groups at each timepoint. Dashed lines represent values recorded at day 0. Data is represented
as mean ± SEM (N = 4 UCB samples) and analyses for statistical significance was performed
using two-way ANOVA followed by a Tukey’s post-hoc multiple comparisons test (*p < 0.05).
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3.4 Culture in hDAT scaffolds stimulated an increase in cells
with high aldehyde dehydrogenase activity
HPC cultured in hDAT scaffolds were also assessed for retention of a functional progenitor
phenotype through quantification of aldehyde dehydrogenase (ALDH) activity using the
AldefluorTM Assay kit. ALDH is a conserved self-protective enzyme that is highly expressed
by hematopoietic progenitor cells and has been found to play an important role in
maintaining the balance between hematopoietic differentiation and self-renewal.158
Following 6 days of expansion, the frequency of ALDHhi HPC was 11.8 ± 2.3 % (Figure 3.4
C). Following 7 days of culture, HPC extracted from the hDAT scaffolds (34.5 ± 8.5, p =
0.06), or HPC collected from the scaffold supernatant (30.9 ± 0.8 %, ***p < 0.001), showed
an increase in the frequency of cells with high ALDH-activity compared to cells cultured on
TCP (1.6 ± 0.3 %). In assessing each treatment group over time, the cells collected from the
supernatant demonstrated an increase in the frequency of ALDHhi cells at day 7 (30.9 ± 0.8
%, **p < 0.01), compared baseline, as well as day 1 (13.7 ± 1.7 %) and day 3 (5.5 ± 1.8 %,
Figure 3.4 C). In contrast, cells cultured on TCP demonstrated a significant decrease in the
frequency of cells with high ALDH-activity at day 3 (2.9 ± 0.8 % **p < 0.01) and 7 (1.6 ±
0.3 %, *p < 0.05) relative to day 1 (8.0 ± 1.2 %) (Figure 3.4 C).
To evaluate if the increased frequency of HPC with high ALDH-activity correlated with an
increase in the frequency of HPC expressing primitive cell surface markers, CD34 expression
was analyzed in the ALDHhi cell population in each treatment group. ALDHhi HPC extracted
from the hDAT scaffolds showed reduced frequency of CD34 expression as early as 3 days
after seeding (11.6 ± 1.6 %, *p < 0.05), and at day 7 (6.8 ± 2.1%, *p < 0.05) relative to day 0
(33.3 ± 0.8 %, Figure 3.4 D). A similar pattern of decreased frequency of CD34 expression
was observed in the ALDHhi HPC collected from the scaffold supernatant. In contrast,
ALDHhi HPC cultured on TCP did not show altered frequency of CD34 expression over time.
Further, the frequency of CD34+ cells in the ALDHhi population was higher in the TCP
cultured cells at day 7 (40.2 ± 2.2 %) as compared to cells extracted from the hDAT scaffolds
(6.8 ± 2.1 %, ***p < 0.001) and cells collected from the scaffold supernatant (5.5 ± 1.1 %,
***p < 0.001, Figure 3.4 D). Taken together, these data suggest that hDAT scaffolds
increased the frequency of ALDHhi cells remaining in the supernatant, but these cells showed
reduced frequency of expression of the primitive cell surface marker CD34.
57

Figure 3.4 HPC collected from the supernatant showed increased ALDH activity in
vitro, with reduced frequency of the primitive cell surface marker CD34 in the ALDHhi
population. (A) Representative flow cytometry plots showing the gating strategy used to
determine cells with high ALDH activity using the ALDH inhibitor, DEAB.
(B) Representative flow cytometry plots showing the frequency of ALDHhi cells extracted
from hDAT scaffolds or collected from the scaffold supernatant, or cultured on TCP at day
7 post-seeding. (C) The frequency of cells with high ALDH activity was increased at day 7
for cells extracted from the hDAT (p = 0.06) and collected from the supernatant
(***p < 0.001), compared to cells cultured on TCP. (D) Cells extracted from the hDAT and
supernatant showed decreased CD34 expression in the ALDHhi population at day 7
compared to cells cultured on TCP (***p < 0.001). Dashed lines represent values recorded
at day 0. Data is represented as mean ± SEM (N = 4 UCB samples) and statistical analysis
was performed using two way ANOVA with a Tukey’s post-hoc multiple comparisons test
(***p < 0.001).
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3.5 Culture in hDAT scaffolds augments expression of
monocyte/macrophage lineage markers in HPC
As UCB-derived ALDHhi cells possess the capacity to differentiate into multiple myeloid
lineages,164, 269 differentiation towards the monocyte, macrophage, and megakaryocyte /
platelet lineages was probed to assess whether culture in hDAT scaffolds modulated HPC
differentiation.270 At day 7 post-seeding, the frequency of CD14+ cells in the population
extracted from the hDAT scaffolds (33.1 ± 2.0 %) was increased compared to the cells
collected from the scaffold supernatant (19.2 ± 3.0 %, *p < 0.05) or HPC cultured on TCP
(4.3 ± 1.4 %, ***p<0.001, Figure 3.5 A,B). The CD14+ cell frequency was also significantly
different between the scaffold supernatant population and the TCP culture group at 7 days
(*p < 0.05). Similar to CD14 expression, CD11b expression was also increased in the cells
extracted from the hDAT scaffolds (34.0 ± 3.9 %, **p < 0.01) and scaffold supernatant (29.6
± 4.2 %, *p < 0.05) compared to HPC cultured on TCP (4.0 ± 1.4 %, Figure 3.5 A,C).
Previous studies from our lab have demonstrated that HPC cultured on TCP under the same
media conditions differentiate preferentially towards the megakaryocyte lineage.206 In the
current study, the frequency of CD42b+ cells was significantly increased at day 3 for cells
cultured on TCP (35.7 ± 4.1 %) compared to day 1 TCP (9.7 ± 1.2 %, *p < 0.05) and day 3
supernatant cells (16.1 ± 3.7 %, *p < 0.05). Positive events for T-lymphocyte (CD3, CD8) or
B-lymphocyte (CD19) lineages were <1% at all timepoints in both hDAT and TCP cultures,
suggesting limited differentiation toward lymphoid lineages. This data suggests that culturing
in the presence of the hDAT scaffolds may have directed HPC differentiation towards the
monocyte/macrophage lineage.
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Figure

3.5

Culture

in

hDAT

scaffolds

results

in

enhanced

expression

of

monocyte/macrophage lineage markers. (A) Representative flow cytometry plots displaying
the frequency of CD14, CD11b and CD42b labelled cells at day 0 and after 7 days of culture for
cell extracted from the hDAT scaffolds, collected from the scaffold supernatant, or on TCP. (B)
The frequency of CD14+ cells was increased in cells extracted from the scaffold relative to cells
collected from the scaffold supernatant (*p < 0.05) or cultured on TCP (***p < 0.001) at day 7.
Cells collected from the scaffold supernatant showed increased CD14+ frequency relative to
TCP (*p < 0.05) at 7 days. (C) Cells extracted from the scaffolds (**p < 0.01) and collected
from the scaffold supernatant (*p < 0.05) showed increased CD11b+ frequency relative to cells
cultured on TCP at 7 days. (D) The frequency of CD42b+ cells was increased at day 3 in the
population cultured on TCP relative to TCP at day 1 (*p < 0.05) and the scaffold supernatant
population at day 3 (*p < 0.05). Dashed lines represent values recorded at day 0. Data is
represented as mean ± SEM (N = 4 UCB samples) and statistical analyses were performed using
two-way ANOVA with a Tukey’s post-hoc multiple comparisons test (*p < 0.05, **p < 0.01,
***p < 0.001).
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3.6 HPC cultured on hDAT scaffolds show upregulated CD163
expression after 7 days
Following the observation that culture in hDAT scaffolds promoted the expression of
markers associated with the monocyte/macrophage lineage, HPC were further analyzed for
CD68, which is enriched on macrophages,271 and CD163, which is commonly used as a
marker of M2 macrophage polarization that is associated with tissue remodeling and provascular function.272 CD68 expression increased over time, with a significant difference
between the frequency of expression at day 7 as compared to day 1 for all groups (Figure 3.6
C).
Based on elevated expression of both macrophage markers CD68 and CD11b at day 7,
expression of CD163 was evaluated to determine the potential polarization toward tissue
remodeling M2 macrophages. At day 7 post-seeding, there was increased CD163 expression
for cells extracted from the hDAT scaffolds (23.6 ± 3.0 %) and collected from the scaffold
supernatant (20.9 ± 2.6 %) as compared to cells cultured on TCP (1.7 ± 0.4 %, ***p<0.001).
Taken together, these results suggest that culturing in the hDAT scaffolds may have
upregulated cell surface markers commonly found on macrophages with an M2-like
macrophage phenotype.
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Figure 3.6 Culture in hDAT promotes CD163+ cell frequency for seeded HPC.
(A) Representative flow cytometry plots displaying the relative frequency of CD68+ cells at
day 0 and after 7 days of culture in populations extracted from hDAT scaffolds, collected from
the scaffold supernatant, or cultured on TCP. (B) Representative flow cytometry plots
showing the frequency of CD163+ cells after 7 days of culture in each of the culturing
methods. (C) Cells extracted from the scaffold demonstrated increased frequency of CD68+
cells at day 7 compared to day 3 (*p < 0.05) and day 1 (*p < 0.05). Cells collected from the
scaffold supernatant showed a stepwise increase of CD68+ expression from day 1 to day 3 and
to day 7 (*p < 0.05). Cells cultured on TCP demonstrated increased CD68+ frequency at day
7 relative to day 1 (*p < 0.05). (D) Cells extracted from the hDAT scaffolds and remaining in
the supernatant had increased CD163+ cell frequencies compared to cells cultured on TCP.
Dashed line represents values recorded at day 0. Data is represented as mean ± SEM (N = 4
UCB samples) and statistical analyses were performed using two way ANOVA with a
Tukey’s post-hoc multiple comparisons test (*p < 0.05, **p < 0.01, ***p < 0.001).
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3.7 Mice treated with HPC delivered in hDAT scaffolds
showed accelerated recovery of limb perfusion
The Hess lab has previously demonstrated that fresh UCB ALDHhi cells and day-6 expanded
HPC have the capacity to accelerate the recovery of perfusion in mice with femoral artery
ligation-induced critical limb ischemia (CLI).164, 165 Following unilateral hindlimb femoral
artery ligation (FAL), non-obese diabetic/severe combined immunodeficient (NOD/SCID)
mice transplanted with HPC-seeded hDAT scaffolds demonstrated an accelerated recovery in
distal hindlimb perfusion. In this group, laser Doppler perfusion imaging (LDPI) ratios
between the ischemic and non-ischemic hindlimbs started at 0.13 ± 0.04 at day 1 and
increased to 0.72 ± 0.13 at day 35 (Figure 3.7 A,B). Similarly, mice receiving an
intramuscular (IM) injection of 5 x 105 day-6 expanded HPC in saline initially showed
accelerated recovery of perfusion at day 7 (0.37 ± 0.15) and day 14 (0.60 ± 0.14). However,
the perfusion ratios decreased to 0.47 ± 0.11 at day 21, before normalizing at 0.54 ± 0.18 at
day 35. Control mice receiving IM injection of saline started with a perfusion ratio of 0.10 ±
0.03 at day 1 and attained a maximal perfusion ratio of 0.49 ± 0.14 at day 35 (Figure 3.7
A,B). Finally, mice transplanted with hDAT scaffolds without HPC demonstrated perfusion
recovery similar to saline injected mice with perfusion ratios of 0.11 ± 0.04 at day 1 and 0.48
± 0.13 at day 35. Overall blood perfusion recovery, evaluated using area under curve (AUC)
quantification, demonstrated significantly increased perfusion recovery after transplantation
of HPC in hDAT (2.77 ± 0.09) compared to mice IM injected with HPC (2.23 ± 0.12,
*p<0.05) or saline (1.82 ± 0.12, ***p < 0.001), or transplanted with hDAT scaffold without
HPC (1.58 ± 0.12, ***p < 0.001). Collectively, these data indicate that HPC delivered in
hDAT scaffolds were capable of stimulating accelerated limb perfusion recovery at early
timepoints and sustaining elevated perfusion up until day 35.
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Figure 3.7 Mice treated with HPC seeded in hDAT scaffolds showed increased limb
perfusion following femoral artery and vein ligation and excision. (A) Representative LDPI
images showing restoration of limb perfusion following FAL surgery and treatment with HPCseeded hDAT scaffolds, IM injection of HPC in saline, scaffold only, or IM injection of saline.
(B) Both HPC-seeded hDAT scaffolds and IM-injected HPC accelerated the recovery of limb
perfusion to day 14. HPC-seeded scaffolds showed increased perfusion ratios to day 35 (*p <
0.05, **p < 0.01. ***p < 0.001, HPC in hDAT vs. Scaffold only). (C) Mice transplanted with
HPC in hDAT experienced greater recovery of limb perfusion, as measured by area under curve
(AUC), relative to mice receiving IM HPC (*p < 0.05), scaffold only (***p < 0.001) and saline
(***p < 0.001). Mice treated with HPC via IM injection in saline demonstrated increased AUC
relative to mice transplanted with the hDAT scaffold only (**p < 0.01). Data represented as
mean ± SEM from 9 mice / group (n = 9) treated with 9 UCB samples (N = 9) and statistical
significance was evaluated using a two-way repeated measures ANOVA, followed by a
Tukey’s post-hoc multiple comparisons test.
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3.8 Mice treated with HPC seeded hDAT showed improved
early limb use compared to saline injected mice
Similar to previous studies by our lab164, mice transplanted with HPC delivered IM or seeded
in hDAT scaffolds demonstrated increased ischemic limb use at day 7 post-transplantation
relative to the saline control group (Figure 3.8). Paw print intensity was evaluated using the
CatWalkTM gait analysis system to determine the weight bearing capacity of the surgical limb
compared to the contralateral hind limb. Paw print intensity ratios were higher at day 7 in
mice transplanted with HPC-seeded in hDAT (0.88 ± 0.03) compared to mice that received
an IM injection of saline (0.67 ± 0.11, *p < 0.05). No significant differences were observed
between treatment groups at day 14 (Figure 3.8 B). The ratio of paw print area comparing the
ischemic and non-ischemic footprint was also evaluated as a measure of limb dexterity
during locomotion. Comparing treatment groups, paw print area ratio was increased at day 7
in mice transplanted with HPC in hDAT (0.57 ± 0.18, *p < 0.05) and IM HPC (0.67 ± 0.03,
*p < 0.05) compared to mice that received IM injection of saline (0.13 ± 0.05). Thus,
improvements in two metrics of functional limb use were observed after HPC transplantation
in hDAT scaffolds, suggesting improved perfusion correlated with improved limb usage.
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Figure 3.8 Mice treated with HPC delivered in hDAT scaffolds showed accelerated
recovery of limb use compared to mice IM injected with saline. (A) Representative
CatWalkTM gait analysis images following limb print identification at day 7 post-surgery. (B)
Paw print intensity ratio was increased at day 7 in mice transplanted with HPC in hDAT
relative to mice that received an IM injection of saline (*p < 0.05). No differences were seen
at day 14. (C) Paw print area ratio was increased at day 7 in mice transplanted with HPC in
hDAT and IM HPC compared to mice that received an IM injection of saline (*p < 0.05). For
the paw print area data, three data points (IM HPC at day 7, PBS at day 7 and 14) were
excluded from the data set following outlier detection by the Grubb’s test with a p < 0.05.
Data represented as mean ± SEM from 5 mice / group (n = 5) treated with 5 UCB samples
(N = 5) and statistical significance was evaluated using a two-way repeated measures
ANOVA with a Tukey’s post-hoc multiple comparisons test.
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3.9 Mice treated with HPC delivered in hDAT scaffolds
showed increased intramuscular capillary density in the
ischemic thigh
Previous studies from the Hess lab have reported that various cell populations derived from
UCB stimulated increased CD31+ vessel density.164, 165, 206 To further investigate the
mechanisms of vascular recovery in mice receiving HPC in hDAT scaffolds, adductor
muscles (thigh) were collected at day 35 and CD31+ vessel area within the ischemic and nonischemic limbs was quantified by histomorphometry. Mice transplanted with scaffold only
(0.52 ± 0.05) or injected with saline (0.52 ± 0.04) demonstrated a significant reduction in
relative CD31+ staining in the ischemic limb relative to the non-ischemic limb at day 35
(Figure 3.9 B). In contrast, mice transplanted with HPC in hDAT (0.91 ± 0.18, ***p < 0.001)
demonstrated significantly increased relative CD31+ area compared to the scaffold alone
group (0.52 ± 0.05). Similarly, mice IM-injected with HPC (0.73 ± 0.19, *p < 0.05)
demonstrated significantly increased relative CD31+ area compared to saline controls (0.52 ±
0.04) (Figure 3.9 B). When evaluating human cell engraftment through immunofluorescent
analysis of human CD45, no human cells were detected in the thigh muscle of mice
sacrificed at day 14 post FAL surgery (Data not shown). These data suggest that HPC
delivered in hDAT scaffolds or injected IM augmented CD31+ vessel density in the ischemic
limb following FAL.
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Figure 3.9 Mice treated with HPC delivered in hDAT scaffolds showed enhanced
intramuscular CD31 expression in the ischemic thigh. (A) Representative adductor muscle
sections stained for CD31 and quantified based on positive pixel counts in mice treated with
HPC-seeded hDAT, scaffold only, IM injection of HPC in saline, or saline alone at day 35 posttransplantation. (B) Average CD31+ area ratio of ischemic : non-ischemic adductor muscles of
mice was increased in mice receiving HPC in hDAT (***p < 0.001) and IM HPC (*p < 0.05)
compared to scaffold only and saline controls. Data represented as mean ± SEM from 9 mice /
group (n = 9) treated with 9 UCB samples (N = 9) and statistical significance was evaluated using
a two-way repeated measures ANOVA, with a Tukey’s post-hoc multiple comparisons test. (*p
< 0.05, ***p < 0.001).
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Chapter 4

4

Discussion

While there has been an intense and ongoing collaborative effort between physicians and
researchers to develop an effective therapy for critical limb ischemia (CLI), a cellular therapy
with the ability to meaningfully reduce patient amputation and mortality rates has remained
elusive. The Hess lab has extensively documented the revascularization potential of
intramuscularly (IM) injected human umbilical cord blood (UCB) derived hematopoietic
progenitor cells (HPC) in immunodeficient mouse models of CLI,165 and has developed an
optimized serum-free expansion protocol to augment regenerative ALDHhi cell numbers
while preserving vascular regenerative functions.164 Unfortunately, due to the creation of a
severely ischemic microenvironment following femoral artery ligation (FAL) surgery and the
predisposition of HPC to migrate to the bone marrow, cell viability and engraftment at the
site of transplantation have been limited.163, 165 As a result, decellularized tissue constructs
have been explored as a delivery platform to enhance cell retention, due to ease of
production, innate bioactivity and biochemical composition that closely resembles native
tissue.237 Notably, human decellularized adipose tissue (hDAT) represents an easily
accessible source of scaffolding material with retained architecture and composition
important for promoting cellular attachment and angiogenesis.259, 273 In the work presented in
this thesis, delivery strategies using cell-supportive hDAT-derived bioscaffolds were
explored as a means to augment cell viability and prolong the regenerative paracrine
secretions of seeded human umbilical cord blood-derived HPC in the ischemic limb of
immunodeficient mice with unilateral FAL.
HPC maintenance, expansion, proliferation and differentiation are guided by a complex set of
microenvironmental cues in the bone marrow niche including chemokines, cytokines,
structural proteins, growth factors, oxygen tension and mechanical forces.274 While the use of
a decellularized tissue scaffold is unlikely to recapitulate all of these signals inherent to the
hematopoietic compartment, hDAT has been shown to be a rich source of structural proteins
and sequestered growth factors also present in endosteal regions of the bone marrow.255
Previous studies by the Flynn lab have comprehensively characterized the proteomic
composition of hDAT-derived scaffolds using mass spectrometry screening techniques and
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identified many relevant structural and bioactive proteins present in the matrix.255 Notably,
the hDAT proteome was found to be primarily composed (>80%) of structural proteins (i.e.
collagen and elastin), glycoproteins and proteoglycans, with a smaller amount of growth
factors and cytokines that have been implicated in signaling pathways critical for
hematopoietic stem cell (HSC) survival and expansion.275 Therefore, hDAT contains
conserved components that may contribute towards guiding hematopoiesis and maintaining
the HPC pool.
In an effort to characterize the impact of the complex microenvironment of the hDAT
scaffolds on the seeded cells and evaluate their applicability as a platform for HPC
transplantation, flow cytometry assays were performed at multiple timepoints to quantify the
survival, proliferation and differentiation of HPC cultured and extracted from within the
hDAT scaffolds relative to the HPC in suspension in the supernatant above the scaffolds, or
HPC cultured on traditional tissue culture plastic (TCP). Cell viability and proliferation were
evaluated to ensure that the scaffolds demonstrated supportive qualities that permitted HPC
infiltration and long-term growth. Interestingly, the studies revealed that cells cultured in
hDAT scaffolds demonstrated increased cell viability and a greater abundance of
proliferating cells compared to cells cultured on TCP. Thus, conducive biophysical and/or
biochemical stimuli were present in the matrix promoting HPC adhesion and cell division.
While it is unclear what specific stimuli facilitated increased cell viability and proliferation,
other studies modelling the endosteal region of bone marrow using 3D collagen gels also
found that CD34+ HPC migrated successfully into the collagen scaffolds and exhibited an
increased frequency of proliferated cells compared to cells grown using conventional culture
techniques.276 Furthermore, this study also demonstrated that increased proliferation was not
limited to cells that directly seeded in the collagen gels but were also observed for HPC
found in suspension above the collagen.276 These findings were also observed in our study
after 7 days of culture with the hDAT scaffolds, suggesting collagen plays an important role
in HPC proliferation. Matrix-induced cell proliferation may be crucial for future translation
of human HPC-seeded hDAT scaffolds, as continued proliferation may promote increased
cell numbers within the scaffold to offset the low seeding efficiency of HPC grown in
suspension above the matrix.
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Another important variable related to cell survival and proliferation within the hDAT
scaffolds is the maintenance of the progenitor phenotype or guidance of differentiation
towards mature hematopoietic lineages. Historically, more primitive hematopoietic cells with
self-renewal capacity have been identified by their cell surface marker expression¾with
CD34+CD38- and CD34+CD133+ cells demonstrating increased long-term hematopoietic
repopulation capacity in immunodeficient mice.134, 140 In order to evaluate how the increased
proliferation impacted HPC phenotype after culture in the hDAT scaffolds, primitive cell
surface marker expression was analyzed through the flow cytometric quantification of
CD34+CD38- or CD34+CD133+ expression at the time of seeding and at day 1, 3 and 7 for
cells extracted from the hDAT scaffolds, collected the scaffold supernatant, or cultured on
TCP. Although no significant differences in CD34+CD38- or CD34+CD133+ frequencies
were observed for HPC on all culturing conditions, cells maintained consistent progenitor
cell surface marker expression across all timepoints, suggesting retention of progenitor cell
populations.
In order to identify and functionally characterize progenitor cells in the hDAT scaffold, high
ALDH-activity was evaluated due to its conserved role as a self-protective enzyme in
multiple progenitor cell lineages.133 Surprisingly, cells extracted from within the hDAT
scaffolds showed a >3 fold increase in the frequency of cells with high ALDH activity at 7
days post-seeding, while a general decline was observed for the cells cultured on TCP. These
data taken alone suggested an increased progenitor cell frequency of cells cultured within the
hDAT scaffolds, but primitive hematopoietic cell surface marker expression remained
equivalent over all timepoints for cells extracted from the hDAT or collected from the
scaffold supernatant. Results published by Leisten et al. also demonstrated no significant
difference in CD34+CD38- frequency of cells cultured on collagen scaffolds compared to
conventional TCP culture.276 Therefore, significantly increased ALDH-activity at day 7
within the scaffold and supernatant groups without a concomitant increase primitive cell
surface marker expression suggested that although ALDH expression was upregulated in
response to factors within the scaffold, primitive cell surface marker expression did not
correlate with high ALDH-activity. For cells cultured on TCP, the ALDHhi cell population
showed elevated CD34 co-expression across all timepoints, suggesting the well-defined
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correlation between ALDH-activity and CD34 expression was preserved in the absence of
hDAT.142
One explanation for an increased frequency of cells with high ALDH-activity may be that
increased oxidative stress was placed on cells in contact with the scaffold due to increased
HPC activation and observed degradation of the scaffolds throughout extended culture.277 In
addition, it was also possible that seeded HPC may have differentiated towards a mature
hematopoietic cell population with elevated ALDH activity. In the seminal study by Storms
et al. that used the Aldefluor assay to identify cells with high ALDH activity, UCB was
found to have two populations of ALDHhi cells with distinct Aldefluor fluorescent intensity
peaks and side scatter (SSC) properties.142 While cells that expressed brighter Aldefluor
fluorescence and higher SSC properties were suspected to be monocytes based on the coexpression of CD14, cells that demonstrated high Aldefluor fluorescence and low SSC
properties were both phenotypically and functionally representative of primitive HPC.142
Likewise, previous work by the Hess lab demonstrated that cells within the
monocyte/macrophage lineage, characterized by the co-expression of the early myeloid
markers CD33 and CD14, typically had elevated ADLH-activity and could be separated from
the more primitive CD34+CD38- cells using SSC properties.163 In the current work, ALDHhi
cells extracted from the hDAT scaffold or remaining in the supernatant qualitatively
exhibited higher SSC relative to ALDHhi TCP cells, thus suggesting that a large proportion of
seeded HPC may have differentiated towards the monocyte lineage.
This project attempted to broadly characterize how hDAT scaffolds influenced HPC
differentiation following extended culture using cell surface markers enriched on various
mature hematopoietic cell lineages. Previous studies have demonstrated that freshly-sorted
ALDHhi UCB primarily consists of early myeloid cells133, 165 that progressively lose
progenitor cell phenotype and selectively differentiate towards the megakaryocyte/platelet
lineage over time when cultured traditionally on TCP.206 Megakaryocytes, are large cells (50
– 100 µm) that can be identified by upregulated expression of the megakaryocyte lineagespecific cell surface markers CD41 (Integrin alpha-IIb) and CD42 (glycoprotein 1b).278
Megakaryocytes are typically found in bone marrow and release cytoplasmic fragments
(mature platelets) into the circulation that function in the clotting cascade and participate in
wound repair following tissue injury.279 The megakaryocyte lineage is relevant to this project
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as megakaryocyte enriched cell populations derived from UCB have shown regenerative
efficacy when intramuscularly (IM) injected into immunodeficient mice with FAL-induced
CLI.206 When evaluating acquisition of megakaryocyte cell surface markers, HPC retained
similar frequencies of CD42b expression across timepoints, independent of the culturing
methodology. This data suggests that either CD42b+ cells migrated directly into the hDAT
and/or some HPC present in the scaffold differentiated towards the megakaryocyte lineage at
a rate equal to TCP. While the presence of megakaryocytes in the hDAT may be a due to
thrombopoietin (TPO) and fms-like tyrosine kinase 3 ligand (Flt-3L) present in the
supplemented media and not factors intrinsic to the hDAT, it is notable that the matrix was
able to harbour large cells capable of promoting angiogenesis and participating in wound
healing processes.
Based on the increased frequency of cells with high ALDH-activity at day 7 that did not coexpress the primitive hematopoietic marker CD34, we next investigated whether cells within
the hDAT scaffold were demonstrating markers of differentiation towards the
monocyte/macrophage lineages. Mononuclear phagocytes consists of monocytes,
macrophages and dendritic cells that function to maintain steady-state tissue homeostasis by
generating an immune reaction in response to infection or tissue inflammation.280 While it
has been recently found that the majority of tissue resident macrophages are present before
birth and maintained throughout adulthood,281 circulating monocytes can be recruited to sites
of infection and inflammation as a secondary response to accelerate tissue repair.280
Monocytes are derived from hematopoietic stem cell precursors in the bone marrow and are
released into circulation where they play a role in both innate and adaptive immunity.282
They are typically thought to consist of a heterogenous population of cells divided into 3
main subsets based on the differential expression of the cell surface markers CD14 and
CD16.283 Cells with high CD14 and low CD16 expression represent a population of classical
inflammatory monocytes that ultimately give rise to non-classical CD14-CD16+ monocytes
through an intermediate CD14+CD16+ stage.283 Each monocyte subset demonstrates a unique
morphology, gene expression profile and function, but have all shown the capacity to
differentiate into macrophages and dendritic cells.284, 285 Due to the essential role that
mononuclear phagocytes play in mediating tissue repair and regeneration17 it is of great
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importance to evaluate whether hDAT promoted HPC differentiation towards these cell
populations.
CD14 was selected as a marker of differentiation towards the monocyte lineage due to its
expression in the initial steps in monocyte development and because classical CD14+CD16monocytes comprise ~85% of the total monocyte pool in the peripheral blood.286 Similarly,
CD11b was selected for its overlapping expression on mature myeloid cells of the monocyte,
macrophage and granulocyte lineages.287 Studies in the Hess lab have previously used these
markers to evaluate monocyte and macrophage differentiation of expanded HPC.164, 206 Flow
cytometric analysis of CD14 and CD11b expression suggested that cells cultured within the
hDAT scaffolds or remaining in the supernatant demonstrated potential differentiation
towards the monocyte lineage with increased frequencies of CD14+ and CD11b+ cells at day
7, compared to cells cultured on TCP. Additionally, increased CD14 and CD11b expression
was only demonstrated at day 7 of culture in the hDAT scaffolds, suggesting that extended
culture in the hDAT was necessary to mediate the upregulation of markers enriched in the
monocyte/macrophage lineage. Interestingly, emergence of CD14+ and CD11b+ cells at day 7
of hDAT culture coincided with observed degradation of the hDAT scaffolds. Similar studies
completed by Ariganello et al. evaluating the impact of decellularized bovine pericardium
(DBP) on macrophage differentiation and polarization found that monocyte-derived
macrophages seeded on DBP had increased matrix metalloproteinase-2 (MMP-2) and matrix
metalloproteinase-9 (MMP-9) activity, as measured by zymography, compared to cells
cultured on TCP.288 While the present study did not evaluate the proteins that hDAT-seeded
HPC secreted, it was evident that cells were degrading the matrix within 7 days of culture.
This indicated that there were seeded cells with high proteolytic activity that could actively
remodel or degrade the hDAT matrix.
To further evaluate HPC differentiation following culture within hDAT scaffolds, the
frequency of cells expressing the cell surface markers CD68 and CD163 were also examined
based on their utility broadly identifying functionally distinct subsets of macrophages.289, 290
Macrophages are believed to exist on a phenotypic spectrum, traditionally defined by
“classically-activated” M1 macrophages and “alternatively-activated” M2 macrophages on
opposing ends, but it is now recognized that there is a complex array of macrophage
phenotypes involved in different aspects of tissue repair and regeneration.281, 285 While M177

like macrophages are believed to regulate the immune response through pro-inflammatory
cytokine release, M2-like macrophage subtypes are characterized by their capacity to
remodel the extracellular matrix (ECM) and resolve tissue inflammation.291 CD68 has been
referred to as a ‘pan-macrophage marker’ due to its relative abundance on both M1 and M2
macrophage subpopulations, with very low expression on basophils, neutrophils and
lymphocytes.271, 292 Cells extracted from the hDAT, collected from the scaffold supernatant,
or cultured on TCP, all demonstrated increased CD68+ cell frequencies compared to day 1,
suggesting minimal influence of the hDAT on CD68 expression. While this was initially
surprising based on the increased CD14 and CD11b expression on HPC in the hDAT,
previous studies evaluating macrophage differentiation on DBP also demonstrated increased
CD68 protein expression at day 7 and 14 for both TCP and matrix cultured cells.288
Within the M2 macrophage spectrum, further characterization has identified three main
subsets (M2a, M2b and M2c) of M2 macrophages that participate in wound healing and
tissue repair.290 Based on the potent angiogenic capabilities and increased phagocytic
capacity of M2c macrophages,290, 293, 294 CD163 expression was evaluated in these studies to
identify cells potentially polarized towards an M2c-like macrophage phenotype.290 CD163 is
a transmembrane glycoprotein primarily found on subsets of human tissue-resident
macrophages, but can also be detected to a lesser extent on circulating peripheral blood
monocytes.295, 296 CD163 is part of the scavenger receptor cysteine-rich superfamily and
functions by binding a broad range of ligands for host defense, red blood cell homeostasis
and regulation of inflammation.297 Indeed, HPC extracted from the hDAT scaffolds or
isolated from the scaffold supernatant demonstrated increased frequencies of CD163+ cells at
day 7 compared to cells cultured on TCP, suggesting potential differentiation towards an
M2c-like monocyte/macrophage phenotype. While the mechanisms guiding the
differentiation response remain unclear, it appeared that the hDAT scaffolds promoted
differentiation of the HPC towards mononuclear myeloid cell lineages capable of remodeling
the hDAT matrix. Of the M2 macrophage subsets, the M2c subset demonstrate high
expression and secretion of enzymes such as MMP-9 that contribute to matrix remodeling
and stimulating angiogenesis.290 Differentiation towards the monocyte/macrophage lineage is
highly relevant to the biomaterial field as many developed matrices have attempted to
modulate the host immune system through the recruitment of monocytes and macrophages
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for tissue regeneration.298 Furthermore, these cell populations are relevant when translating to
in vivo experiments, as monocytes and macrophages have previously demonstrated important
roles in angiogenesis, revascularization and tissue repair.299 By engineering a matrix with the
capacity to guide HPC differentiation towards proangiogenic cell populations, the delivery of
potent regenerative stimuli to regions of ischemia may facilitate tissue repair and augment
blood vessel regeneration.
Previous studies in the Hess lab have thoroughly characterized the ability of fresh or day-6
expanded ALDHhi HPC derived from UCB to stimulate revascularization in immunodeficient
mice with surgically-induced hind-limb ischemia.164, 165 This project attempted to improve
HPC viability at the site of transplantation and prolong the pro-angiogenic paracrine function
of HPC using a cell-supportive delivery strategy within hDAT implants. It was found that
transplantation of HPC-seeded hDAT scaffolds in immunodeficient mice with acute
unilateral hindlimb ischemia resulted in accelerated perfusion recovery compared to PBSinjected or unseeded scaffold implantation, with significantly augmented perfusion observed
as early as day 7 post-transplantation. Notably, while mice treated with an IM injection of
HPC also demonstrated accelerated recovery in perfusion of the ischemic limb until day 14,
only mice treated with the HPC-seeded in hDAT maintained elevated perfusion out to day
35. These data suggested that mice receiving an IM injection of HPC received similar
regenerative stimuli at early timepoints, but ultimately plateaued earlier in recovery. Only
mice transplanted with HPC seeded in hDAT demonstrated sustained perfusion, eluding to a
more potent revascularization capacity and/or sustained regenerative effect. Further analysis
evaluating the area under the curve (AUC) for each treatment condition was performed to
gain insight on the total perfusion recovery over the 35 days following surgery. Of the
treatment conditions, HPC seeded in hDAT demonstrated an increased AUC compared to IM
injected HPC, unseeded hDAT scaffolds and IM injected saline, suggesting that total
perfusion recovery over the 35 day was improved. Overall, HPC seeded in hDAT scaffolds
demonstrated the capacity to improve the recovery trajectory and total perfusion over time in
immunodeficient mice following unilateral FAL.
Next, to corelate improved perfusion recovery with functional limb use, CatWalk gait
analysis was performed at day 7 and 14 post-surgery. Paw print intensity and area were
selected as criteria to evaluate the weight bearing capacity of the limb and paw dexterity,
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respectively. Previous studies by the Hess lab have demonstrated that mice IM injected with
day-6 expanded HPC had improved paw print intensity at day 7 following FAL.164 No other
metrics of functional recovery were reported.164 In the present study, mice transplanted with
HPC seeded in hDAT scaffolds and those IM injected with HPC had increased paw print area
and values compared to mice IM injected with saline. However, only mice transplanted with
HPC seeded in hDAT demonstrated increased paw print intensity compared to those
receiving an IM injection of saline. This indicated that while both cell treatment groups were
effective in improving metrics of limb dexterity, only mice transplanted with HPC in hDAT
were capable in improving the weight bearing capacity of the surgical limb compared to
saline controls. It is important to note however, that mice transplanted with unseeded hDAT
scaffolds demonstrated a similar recovery of functional limb use compared to HPC seeded
hDAT and IM injected HPC treatment groups. While these improvements in limb use were
unexpected based on decreased recovery of limb perfusion and CD31+ vessel density, the
CatWalk gait analysis assay may not be sensitive enough to record smaller differences
between treatment groups and further experiments involving more N values should be
performed. Overall, these data suggest that HPC delivered in the hDAT scaffolds or injected
IM were successful in delivering angiogenic stimuli capable of improving early functional
limb use when compared to mice injected with saline in relevant surgically induced animal
models of CLI.
In an attempt to identify the underlying mechanism of perfusion and functional recovery,
immunohistochemical analysis was completed to evaluate CD31+ vessel density. CD31
(PECAM-1) is a cell surface marker found on endothelial cells that is commonly used to
identify small vessels in histological sections.300 When looking at the response at 35 days
after transplantation, the CD31+ vessel density within the thigh muscles of mice transplanted
with HPC seeded in hDAT scaffolds and those IM injected HPC were significantly increased
compared to the scaffold only or IM-saline injection groups. These finding suggest that HPC
were able to secrete paracrine factors that increased CD31+ vessel density and corelated with
improved limb perfusion and functional limb use. While it is unknown what angiogenic
stimuli was secreted by the HPC to mediate these changes in CD31+ vessel density, other
studies analyzing the gene expression of HPC cultured on collagen gels found that genes
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encoding the potent angiogenic cytokines IL-8, CXCL2 and HGF were upregulated on HPC
following culture on collagen.301
Finally, the ability of the hDAT scaffolds to retain HPC at the site of transplantation and
promote engraftment into the ischemic tissue was evaluated by immunofluorescent staining
for human-specific CD45. CD45 is a transmembrane cell surface marker found on all
nucleated human hematopoietic cell lineages and was used to evaluate human cell
engraftment in the ischemic thigh muscle.302 When attempting to evaluate HPC retention at
day 14, it was found that hDAT scaffolds seeded with HPC had degraded rapidly and were
undetectable at the site of transplantation. This was most likely due to the proteolytic activity
of HPC seeded into the matrix as scaffolds were typically found intact in mice that were
transplanted with hDAT without HPC. Additionally, previous studies completed by the Flynn
lab have shown that hDAT scaffolds seeded with or without adipose-derived stromal cells are
detectable up to 12 weeks after surgery when implanted into immunocompetent rats.259 When
evaluating HPC engraftment into the ischemic tissue, no CD45+ human cells were detected at
day 14 in the thigh sections of mice transplanted with HPC seeded in hDAT scaffolds or IM
injected with HPC. Notably, this two week post-surgery evaluation of human cell
engraftment exceeds the maximum point of detection in previously conducted studies
evaluating human cell engraftment of IM injected HPC (<7 days).165 Overall, these studies
supported the use of HPC seeded hDAT scaffolds for promoting the revascularization of the
ischemic limb of mice following FAL. However, future studies need to be completed at
earlier timepoints (7 and 10 days) to more accurately assess the cell retentive and
engraftment qualities of the hDAT scaffolds.
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Chapter 5

5

Conclusions and future directions

5.1 Summary of findings
In objective 1, this project sought to characterize the interaction between the human
umbilical cord blood (UCB)-derived hematopoietic progenitor cells (HPC) and decellularized
adipose tissue (hDAT) scaffolds. HPC were expanded for 6 days following purification based
on high ALDH-activity, seeded into hDAT scaffolds, and cell viability, proliferation and
phenotype were analyzed at day 1, 3 and 7 by flow cytometry. Compared to HPC grown on
TCP, HPC seeded in the hDAT scaffolds showed an increased cell viability as early as day 3
that was sustained over the 7-day culture period. Interestingly, while cells remaining in the
scaffold supernatant or cultured in suspension on TCP demonstrated decreasing cell viability
across 7 days of culture, HPC extracted from the hDAT showed maintained cell viability
across timepoints. Similarly, the hDAT scaffolds also supported the growth of seeded HPC,
with increased frequency of proliferating cells at day 7 for HPC cultured on hDAT compared
to cells cultured on TCP. Furthermore, HPC extracted from hDAT scaffolds demonstrated
sustained frequencies of proliferation over the 7 days of culture while cells remaining in the
supernatant and cultured on TCP demonstrated decreases from day 1 to 7. Therefore, these
results confirmed hDAT supported HPC survival and stimulated proliferation compared to
traditional suspension culture on TCP.
Next, cell phenotype was evaluated through the flow cytometric analysis of the co-expression
of primitive cell surface markers and ALDH activity. The cell surface markers CD34, CD133
and CD38 were first examined based on previous evidence supporting the enrichment of
NOD/SCID repopulating cells within CD34+CD38- and CD34+CD133+ fractions of UCB.134,
140

Aldehyde dehydrogenase (ALDH) was selected due to its conserved role as a self-

protective enzyme within many stem cell lineages and high correlation with CD34 and
CD133-expressing HPC.133, 142 HPC extracted from hDAT scaffolds, collected from the
scaffold supernatant or cultured on TCP each demonstrated a low and equivalent frequency
of CD34+CD38- and CD34+CD133+ cells throughout 7 days of culture, with the exception of
a decreased frequency of CD34+CD133+ between days 1 and 7 for cells remaining in the
supernatant. Looking at the frequency of cells with high ALDH-activity, cells remaining in
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the supernatant showed an increased frequency of ALDHhi cells at day 7 compared to day 1,
and an increased frequency of ALDHhi cells at day 7 compared to cells cultured on TCP at
day 7. HPC cultured on hDAT trended towards an increased frequency of ALDHhi cells
compared to day 1 values (p = 0.06) and when compared to cells cultured on TCP for 7 days
(p = 0.07). When the ALDHhi cells were evaluated for the co-expression of the primitive cell
surface marker CD34, cells cultured on hDAT scaffolds or remaining in the supernatant
demonstrated a reduced frequency of ALDHhiCD34+ cells, while cells cultured on TCP
retained high levels of ALDH and CD34 co-expression. These data indicated that the
increased frequency of cells with high ALDH-activity was independent of primitive cell
phenotype, and suggested that HPC may have differentiated into mature myeloid cells with
elevated ALDH-activity.142, 163
To evaluate how culture in hDAT scaffolds influenced HPC differentiation, cell surface
marker expression associated with the monocyte, macrophage and megakaryocyte (platelet)
lineages was analyzed using CD14, CD11b and CD42b expression, respectively.279, 286, 287
Culture of HPC in hDAT scaffolds augmented HPC differentiation towards the
monocyte/macrophage lineage with both CD14 and CD11b expression increased at day 7
compared to cells cultured on TCP. Interestingly, cells cultured in hDAT demonstrated the
greatest enrichment of CD14+ cells, suggesting that the scaffolds had instructive effects in
promoting monocyte/macrophage differentiation. When evaluating the frequency of cells
with megakaryocyte marker CD42b, only cells cultured in suspension on TCP showed
increased CD42 expression from day 1 to 3. No other changes in CD42b frequencies were
observed, indicating megakaryocytes were maintained at all timepoints for all culturing
methodologies.
Following the observations that the frequency of CD14 and CD11b were increased for cells
extracted from the hDAT or collected from the scaffold supernatant, the expression of the
cell surface markers CD68 and CD163 was analyzed based on their common use as
indicators of macrophage differentiation and M2c macrophage polarization, respectively.292,
295

Interestingly, all groups demonstrated increased CD68 expression at day 7 compared to

day 1, indicating that culture itself rather than the exposure to hDAT was influential in
driving CD68 expression. CD163+ cell frequencies were increased at day 7 for cells cultured
in hDAT scaffolds and remaining in the supernatant. Taken together, these data suggest that
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HPC cultured in the hDAT scaffolds or remaining in the supernatant show upregulation of
markers enriched on the macrophage lineage, with increased frequencies of CD163 as a
marker of M2c-like macrophage polarization.
For objective 2, in vivo analyses were performed to assess the regenerative capacity of HPC
seeded in hDAT scaffolds in immunodeficient non-obese diabetic/severe combined immune
deficient (NOD/SCID) mice following femoral artery and vein ligation and excision. Herein,
it was demonstrated that day-6 expanded ALDHhi HPC seeded within decellularized adipose
scaffolds facilitated an accelerated recovery in distal hind-limb perfusion following FAL
surgery. Improved perfusion was sustained until the end of the assay at day 35. When
evaluating the capacity of HPC delivered within hDAT scaffolds for improving functional
metrics of limb use, treatment with the cell-seeded scaffold was shown to increase surgical
limb paw print intensity and area compared to mice IM injected with saline alone. To
evaluate the underlying mechanisms of recovery in functional limb use and hind-limb
perfusion, CD31 vessel area of the ischemic and non-ischemic thighs were evaluated at day
35. Mice that were transplanted with HPC-seeded hDAT scaffolds or IM injected with day-6
expanded HPC demonstrated increased CD31+ vessel area compared to mice transplanted
with hDAT alone or IM injected with saline. When assessing human cell engraftment at day
14 through human-specific CD45 immunohistochemical analysis, no human CD45+ cells
were detected in the ischemic thighs of either cell treatment group at day 14, suggesting that
long-term retention was not required for observed improvements.

5.2 Limitations and future recommendations
The current study attempted to quantitatively characterize the interaction between the hDAT
scaffolds and UCB-derived HPC over 7 days of in vitro culture and offered support for the
use of the cell-seeded matrix in promoting in vivo revascularization in surgically induced
animal models of CLI. Future studies assessing HPC behaviour within hDAT matrix and
more fully evaluating the mechanisms of vascular regeneration within in vivo models of CLI
need to be completed for a better understanding of the applicability of hDAT scaffolds for
HPC delivery. Additionally, other cell delivery strategies harnessing injectable hDAT
microcarriers could be explored with seeded HPC for a more clinical translatable therapy.303

84

Although the characterization of the viability, proliferation and cell phenotype of HPC
seeded in the hDAT were thorough and highly quantitative, all of the in vitro assays were
performed using flow cytometry and thus relied on cell frequencies for interpretation. While
these analyses were effective in evaluating the proportion of cells positive for each marker
within each culture condition, the total number of cells seeded and present in each scaffold
remained unknown. Future studies will need to be completed to evaluate the magnitude of
HPC attachment and infiltration into the hDAT scaffolds so that these values can be directly
compared with the quantity of cells present in the supernatant or cultured on TCP.
Immunohistochemistry has proven to be an effective tool in evaluating cell density within
many other biomaterial studies and could be employed alongside flow cytometric analysis to
provide further insight on cell behaviour within the hDAT matrix.259, 304 In particular,
measures of cell viability, proliferation and cell phenotype could be repeated using
fluorescent microscopy analyses using CellTracker green CMFDA dye,305 Click-iT EdU cell
proliferation assay,306 and/or antibodies specific for cell surface markers indicative of cell
phenotype (i.e. CD34, CD38, CD133, ALDH1A1, CD14, CD11b, CD163, CD206),
respectively. By pairing the EdU and cell surface marker IHC assays together, information
on what cell phenotype is proliferating could be evaluated. Although these analyses may be
less quantitative than flow cytometry, they could be combined with stereology to offer
quantitative insight on the spatial distribution of seeded HPC and the maturation of
hematopoietic progeny within the hDAT scaffold. Alternatively, fluorescent flow cytometry
counting beads could be used to obtain an absolute cell number of cells present in the
scaffold following enzymatic digestion.307
It is important to note that many of the cell surface markers employed in this study are not
exclusive to a specific cell population, but generally provide an indication of differentiation
towards a particular cell lineage. For example, while CD14, CD11b and CD68 are useful
markers to broadly evaluate the induction of monocytopoiesis within hDAT scaffolds, it is
difficult to draw firm conclusions on what specific cell types are present in the matrix
because the markers detected may also be present on other myeloid populations, such as
granulocytes.287, 308 Therefore, future studies could use additional myeloid markers in unison
with the ones selected in this project to give a more in-depth understanding of the cell
populations present in the hDAT scaffold. For example, flow cytometry panels involving
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CD66b and CD15 alongside CD11b, CD14, CD68, and CD16 could be developed for a better
interpretation of the frequency of granulocyte and monocyte cell differentiation,
respectively.309, 310 For the megakaryocyte lineage, CD41 in unison with CD42 and CD38
expression could be used to identify more primitive CD41+CD42- megakaryoblasts before the
upregulation of CD42 and CD38 during megakaryocyte maturation.206 Finally, while T(CD3 and CD8) and B-lymphocyte (CD19) induction was not demonstrated in the hDAT
scaffolds, other lymphocyte populations such as natural killer (NK) cells, remain to be tested.
Similar studies evaluating HPC differentiation in collagen scaffolds found that CD56, a
marker representative of human NK cells, was upregulated in cells in the suspension above
the matrix and on TCP.276 While they reported reduced expression of CD56 on HPC cultured
in collagen, it still may be important to evaluate if hDAT is able to induce differentiation
towards a non-myeloid lineage.
Another important question that arose following the observation that hDAT promoted the
upregulation of cell surface markers commonly enriched in the monocyte/macrophage
lineage was whether the hDAT was capable of directing macrophage polarization to a proregenerative phenotype. This study selected CD163 for its enrichment on macrophages with
M2c polarization that play a prominent role in ECM remodeling and wound healing.295
Similar to the issues arising with the use of CD14 and CD11b, CD163 on its own does not
give a conclusive representation of what cells are present in the matrix, due to it being
present on multiple macrophage populations.311 Future studies fully examining multiple
markers of macrophage polarization through flow cytometry and IHC could be utilized for a
more complete characterization of the macrophage subsets present in the matrix. Cell surface
markers such as CD80, CD64 and/or CD86, and CD206, CD200R and/or CD163 could be
examined in unison with CD68 for a more accurate portrayal of the frequency of M1 and M2
macrophages, respectively.290, 295, 312
While the updated flow cytometry panels would provide a more complete overview of
hematopoietic lineages present by cell surface marker expression, assays measuring the
functional differentiation capacity of cells cultured in the hDAT remain to be performed.
Clonogenic assays could be employed to evaluate the differentiation potential of cells
extracted from the hDAT, remaining in the supernatant or cultured on TCP through
quantitative measurement of colony formation with morphology indicative of erythrocytes
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(BFU‐E), granulocytes (CFU‐G), macrophages (CFU‐M), granulocytes/macrophages (CFU‐
GM), or mixed (CFU‐Mixed) hematopoietic cells.313 Previous studies by the Hess lab
analyzing the hematopoietic colony formation of UCB-derived fresh ALDHhi HPC and HPC
cultured for 6 or 9 days on TCP found that the frequency of total hematopoietic colony
formation was decreased with extended culture. Furthermore, CFU-G and CFU-M frequency
was decreased at 6 and 9 days of culture, indicating a reduction in myeloid precursors over
culture.164 With upregulation of cell surface markers commonly enriched on monocyte and
granulocyte populations following culture in hDAT, it would be interesting to evaluate the
colony forming capacity of HPC after culture on hDAT compared to HPC cultured on TCP.
Further work also needs to be performed in vivo. Studies need to be completed evaluating the
degradation of the hDAT scaffold and the capacity to support HPC engraftment at the site of
transplantation at earlier timepoints. In previous studies involving IM injection of HPC into
the thigh muscle of mice following FAL, human cells were rarely detected past 7 days postinjection.164 Future studies should be designed to carefully assess human cell engraftment
using the cell tracking NOD/SCID/mucopolysaccharidosis type VII (MPSVII) mouse model.
NOD/SCID/MPSVII mice are deficient in beta-glucoronidase (GUSB) activity allowing for
the detection of human cells with ubiquitously expressed GUSB activity at single cell
sensitivity.314 Previous studies using the MPSVII mouse have detected individual human
cells in the thigh tissue, with the added benefit of being able to co-stain GUSB activity with
vessel markers such as von-Willebrand factor (vWF).165 Additionally, detailed in situ
analysis of endothelial cell proliferation within the thigh muscle surrounding the implantation
site could be assessed following EdU injection prior to euthanasia and staining using
fluorescent antibodies targeting the murine vessel marker, CD31.164
Finally, different methodologies evaluating hind limb perfusion and blood flow dynamics in
the ischemic limb could be developed to confirm the laser Doppler perfusion imaging data.
In collaboration with Dr. James Lacefield at Robarts Research Institute, novel imaging
modalities such as power Doppler and contrast enhanced ultrasound could be used to gain
further insight on the collateral vessel formation within the ischemic limb for further
detailing of the underlying mechanisms of vascular recovery.315 These ultrasound imaging
modalities have been successful in quantifying blood flow dynamics to tumours implanted in
the mammary fat pad of mice in a breast cancer xenograft model.315 Preliminary application
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of power Doppler ultrasound on the ischemic and non-ischemic limbs are shown in
Supplementary Figure 1, where small vessels are clearly visible following a post scan
filtration algorithm. Altogether, these future investigations will more accurately evaluate
HPC behavior within the hDAT scaffolds and help clarify the underlying mechanisms of
perfusion recovery and improved functional limb use.

5.3 Conclusion
With the rising prevalence of PAD in the global population, there remains a large number of
CLI patients who are ineligible for traditional surgical revascularization and require an
effective therapy that can stimulate new blood vessel growth and improve patient
outcomes.59 Previous studies evaluating the regenerative potential of expanded umbilical
cord blood-derived hematopoietic progenitor cells found that intramuscularly-injected cells
were capable of restoring limb perfusion in a surgical model mouse model of CLI, but
demonstrated poor cell viability and engraftment at the ischemic site in mice.164 These
multidisciplinary studies aimed to provide pre-clinical proof-of-concept for an improved
cellular therapy strategy for CLI using a cell-supportive matrix derived from human
decellularized adipose tissue. hDAT was shown to promote the viability and proliferation of
seeded HPC, and had cell-instructive effects on HPC differentiation, with increased
expression of cell surface markers associated with the monocyte/macrophage lineages. When
translated in vivo, HPC seeded hDAT scaffolds were shown to promote revascularization in
an established animal model of CLI and correlated with improvements in perfusion, limb use
and small vessel density. Altogether, the present work supports the potential use of hDAT
scaffolds as a cell delivery platform for UCB-derived HPC for therapeutic applications
requiring revascularization and vessel regeneration.
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Appendices
Appendix. 1 Supplementary Figures

A

B

C

Supplementary figure 1. Preliminary images highlighting the utility of power doppler
ultrasound at day 35 post FAL surgery. Images were taken in collaboration with Mahsa
Bataghva Shahbaz of Dr. James Lacefield’s lab and analyzed with a currently underdevelopment filtration algorithm used to reduce clutter and emphasize microvascular blood
flow. (A) Representative images of blood flow detected using power doppler ultrasound prior
to any post-scan filtration algorithms. (B) Vasculature detected in the non-surgical leg of mice
following ultrasound data filtration algorithm developed by Mahsa. (C) Vasculature detected
in the surgical leg of mice following ultrasound data filtration. Relevant vasculature signal
highlighted by white arrows.
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